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A B S T R A C T
Background
Epidemiological evidence has suggested a link between beta2-agonists and increases in asthma mortality. There has been much debate
about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are safe when used alone or in
conjunction with inhaled corticosteroids.
Objectives
The aim of this review is to assess the risk of fatal and non-fatal serious adverse events in trials that randomised patients with chronic
asthma to regular formoterol with inhaled corticosteroids versus the same dose of inhaled corticosteroids alone.
Search methods
Trials were identified using the Cochrane Airways Group Specialised Register of trials. Web sites of clinical trial registers were checked
for unpublished trial data and Food and Drug Administration (FDA) submissions in relation to formoterol were also checked. The
date of the most recent search was October 2008.
Selection criteria
Controlled parallel design clinical trials on patients of any age and severity of asthma were included if they randomised patients to
treatment with regular formoterol and inhaled corticosteroids, and were of at least 12 weeks duration.
Data collection and analysis
Two authors independently selected trials for inclusion in the review. Outcome data were independently extracted by two authors.
Unpublished data on mortality and serious adverse events were obtained from the sponsors.
Main results
The review included 14 studies on adults and adolescents (8,028 participants) and seven studies on children and adolescents (2,788
participants). Data on all cause fatal and non-fatal serious adverse events were found for all studies, and the overall risk of bias was low.
Four deaths occurred on regular formoterol with inhaled corticosteroids, and none on regular inhaled corticosteroids alone. All the
deaths were in adults, and one was reported to be asthma-related. The difference was not statistically significant.
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Non-fatal serious adverse events of any cause were very similar in adults [Peto Odds Ratio 0.99 (95% CI 0.74 to 1.33)], and an increase
in events in children on regular formoterol was not statistically significant [Peto Odds Ratio 1.62 (95% CI 0.80 to 3.28)].
Asthma related serious adverse events on formoterol were lower in adults [Peto Odds Ratio 0.53 (95% CI 0.28 to 1.00)] and although
they were higher in children [Peto Odds Ratio 1.49 (95% CI 0.48 to 4.61)], this was not statistically significant.
Authors’ conclusions
It is not possible, from the data in this review, to reassure people with asthma that inhaled corticosteroids with regular formoterol
carries no risk of increasing mortality in comparison to inhaled corticosteroids alone as all four deaths occurred among 6,594 people
using inhaled corticosteroids with formoterol. On the other hand, we have found no conclusive evidence of harm and there was only
one asthma related death registered during over 3,000 patient year observation on formoterol. In adults, the decrease in asthma-related
serious adverse events on regular formoterol with inhaled corticosteroids was not accompanied by a decrease in all cause serious adverse
events. In children the number of events was too small, and consequently the results too imprecise, to determine whether the increase in
all cause non-fatal serious adverse events found in the previous meta-analysis on regular formoterol alone is abolished by the additional
use of inhaled corticosteroids. Clinical decisions and information for patients regarding regular use of formoterol have to take into
account the balance between known symptomatic benefits of formoterol and the degree of uncertainty and concern associated with its
potential harmful effects.
P L A I N L A N G U A G E S U M M A R Y
Serious adverse events with regular formoterol and inhaled corticosteroids
There has been some concern raised at the possibility of increased serious adverse events following administration of formoterol, a
long-acting beta-agonist, to people with asthma. We analysed data from 14 studies in adults and seven in children. Too few deaths
occurred in the trials to gain any conclusive reassurance that regular formoterol taken with inhaled corticosteroids either reduces the
risk of mortality, or in fact does not increase it (all four deaths that did occur, including one related to asthma, were among 6,594
patients taking formoterol with inhaled corticosteroids). Serious adverse events were very similar in adults with and without formoterol.
Although there were more events on formoterol in children, the difference was not big enough to rule out this as being a chance finding.
Similarly, decreased risk of asthma-related serious adverse events in adults and increased risk among children taking formoterol could
be also be chance findings.
B A C K G R O U N D
When patients with asthma are not controlled by low dose inhaled
corticosteroids alone, many asthma guidelines recommend addi-
tional long-acting beta2-agonists. Several Cochrane reviews have
addressed the efficacy of long-acting beta2-agonists in addition to
inhaled corticosteroids (Ni Chroinin 2004; Ni Chroinin 2005), in
comparison with placebo (Walters 2007), short-acting beta2-ago-
nists(Walters 2002), leukotriene-receptor antagonists (Ducharme
2006) and assessed them against increased doses of inhaled corti-
costeroids (Greenstone 2005). The beneficial effects of long-act-
ing beta2-agonists on lung function, symptoms, quality of life and
exacerbations requiring oral steroids have been demonstrated.
However, there is also longstanding controversy over the regular
use of beta2-agonists in asthma. Sears 1986 suggested that exces-
sive use of short acting beta2-agonists might have contributed di-
rectly or indirectly to increases in asthma deaths in New Zealand
between 1960 and 1980. The authors comment that “most deaths
were associated with poor assessment, underestimation of sever-
ity and inappropriate treatment (over-reliance on bronchodilators
and under use of systemic corticosteroids), and delays in obtaining
help.”
Concern remains that the symptomatic benefit from treatment
with long-acting beta2-agonists might lead to underestimation of
attack severity in acute asthma, and could lead to an increase in
asthma-related deaths. Furthermore, regular treatment with beta2-
agonists can lead to tolerance to their bronchodilator effects and
this phenomenon may be more marked with longer acting as op-
posed to shorter acting compounds (Lipworth 1997). A number
of molecular mechanisms have been proposed to explain the possi-
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ble detrimental effect of long-term beta2-agonist use in asthma in-
cluding receptor down regulation and desensitisation (Giembycz
2006).
There are two currently available long-acting beta2-agonists, sal-
meterol and formoterol (also known as eformoterol). These two
drugs are known to have differences in speed of onset and recep-
tor activity, and are used in different ways (for example salme-
terol has a slower onset of action than salbutamol Beach 1992
and is therefore unsuitable for use as a reliever). ’The Fenoterol
Story’ is a reminder that all beta2-agonists may not carry the same
risks (Pearce 2007), so in view of the potential difference in ad-
verse effects between salmeterol and formoterol, we have consid-
ered the two drugs separately. Two recent systematic reviews have
addressed the impact of long-acting beta2-agonists on all cause
mortality and serious adverse events: Cates 2008 (salmeterol) and
Cates 2008a (formoterol). Both reviews considered long-acting
beta2-agonists which were randomised without additional inhaled
corticosteroids and demonstrated increased risks of non-fatal seri-
ous adverse events.
There has been much debate about the interaction between in-
haled corticosteroids and long-acting beta2-agonists, in relation
to serious adverse events, since the publication of SMART 2006.
This study did not randomise patients to inhaled corticosteroids,
but nevertheless a subgroup analysis of the results was carried out
on the basis of inhaled corticosteroid use at baseline. It is tempting
to find reassurance from the fact that there was not a statistically
significant increase in asthma-related mortality in the subgroup
using inhaled corticosteroids, but this is not the correct way to test
for interaction (Altman 2003), and no assessment was carried out
during the trial in relation to the actual use of inhaled corticos-
teroids during the course of the study.
Counfounding by severity has been shown by Sears 2008 in data
from the RELIEF study, where the rate of asthma-related SAEswas
significantly higher in both arms of the study in patients taking
ICS in comparison to those not taking ICS. This is a serious
threat to any conclusions drawn from observational data when
assessing the interaction between ICS and formoterol. Therefore,
there is a need to systematically review all the available data from
controlled trials that randomised patients to regular formoterol
in combination with inhaled corticosteroids, and to consider all
serious adverse events (fatal and non-fatal), whether or not these
are deemed by the investigators to be related to trial medication.
The focus of this review is therefore on regular formoterol ran-
domised in combination with inhaled corticosteroids, (in a single
inhaler or separate inhalers) and compared to inhaled corticos-
teroids alone. Due to the difficulty in deciding whether adverse
events are asthma-related, this review will focus on studies that
capture mortality and serious adverse events, and record both all
cause outcomes, and those considered by the trial investigators to
be asthma-related events.
A review comparing regular salmeterol randomised in combina-
tion with inhaled corticosteroids, (in a single inhaler or separate
inhalers) and compared to inhaled corticosteroids alone is also
currently ongoing.
O B J E C T I V E S
To assess the risk of mortality and non-fatal serious adverse events
in trials which randomise patients with chronic asthma to regular
formoterol and inhaled corticosteroid in comparisonwith the same
dose of inhaled corticosteroid.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Controlled parallel design clinical trials, with or without blinding,
in which formoterol and inhaled corticosteroid were randomly
assigned to patients with chronic asthma in comparison to the
same dose of inhaled corticosteroid alone. Studies on acute asthma
and exercise induced bronchospasm have not been included.
Types of participants
Patients with a clinical diagnosis of asthma of any age group, un-
restricted by disease severity, previous or current treatment.
Types of interventions
Inhaled corticosteroids and formoterol given regularly once or
twice daily for a period of at least 12 weeks, at any dose and de-
livered by any single or separate devices (CFC-MDI, HFA-MDI,
DPI). Studies that randomised patients to formoterol and inhaled
corticosteroids for intermittent use as a reliever have not been in-
cluded in this review, and studies that compared different doses
of formoterol, or different delivery devices or propellants with-
out a placebo arm were also not be included. Studies in which
formoterol was randomised without an inhaled steroid have been
considered in a separate review (Cates 2008a). Studies that use
comparison groups with the same dose and type of inhaled corti-
costeroids in the control arm will be included in this review, and
co-intervention with leukotriene receptor antagonists, cromones
or theophylline will be allowed as long as they are not part of the
randomised intervention, and are therefore not systematically dif-
ferent between groups. Studies comparing formoterol to salme-
terol will be subject to another review and were not included in
this review. We have also excluded in this review studies in which
3Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
inhaled corticosteroids were used in all patients as background
treatment (rather than randomised intervention).
Types of outcome measures
Primary outcomes
1. All cause mortality
2. All cause non-fatal serious adverse events
Secondary outcomes
1. Asthma-related mortality
2. Asthma-related non-fatal serious adverse events
3. Respiratory-related mortality
4. Respiratory-related non-fatal serious adverse events
5. Cardiovascular-related mortality
6. Cardiovascular-related non-fatal serious adverse events
7. Asthma-related non-fatal life-threatening events (intubation
or admission to intensive care)
8. Respiratory-related non-fatal life-threatening events
(intubation or admission to intensive care)
Outcomes will not be sub-divided according to whether the trial
investigators considered them to be related to trial medication.
Search methods for identification of studies
Electronic searches
Trials were identified using the Cochrane Airways Group Spe-
cialised Register of trials, which is derived from systematic searches
of bibliographic databases including the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED, and PsycINFO, and hand searching of respira-
tory journals and meeting abstracts. All records in the Specialised
Register coded as ’asthma’ will be searched using the following
terms:
(((beta* and agonist*) and (long-acting or “long acting”)) or ((beta*
and adrenergic*) and (long-acting or “long acting”)) or (bron-
chodilat* and (long-acting or “long acting”)) or (salmeterol or for-
moterol or eformoterol or advair or symbicort or serevent or sere-
tide or oxis)) AND (serious or safety or surveillance or mortality
or death or intubat* or adverse or toxicity or complications or
tolerability)
Searching other resources
Reference lists of all primary studies and review articles were
checked for additional references. Web sites of clinical trial regis-
ters were checked for unpublished trial data and FDA submissions
in relation to formoterol were also checked.
Data collection and analysis
Selection of studies
Two review authors independently assessed studies identified in
the literature searches by examining titles, abstract and keywords
fields. Studies that potentially fulfilled the inclusion criteria were
obtained in full text. These were independently assessed by CJC
and TL for inclusion. Disagreements were resolved by consensus.
Data extraction and management
Datawere extracted using a prepared checklist before being entered
into Rev Man 5.0 by one reviewer (CJC), and data extraction and
entry were checked by a second reviewer (TL). Outcome data were
independently extracted by the third reviewer (RJ) and discrepan-
cies resolved by correspondence with the sponsors. Data included
characteristics of included studies (methods, participants, inter-
ventions, outcomes) and results of the included studies. Sponsors
of included studies were contacted for unpublished adverse event
data, and the sponsors’s web site was searched for further details of
adverse events. All cause serious adverse events (fatal and non-fatal)
were recorded, and in view of the difficulty in deciding whether
events are asthma related, details of the cause of death and serious
adverse events were noted where they are available. The definition
of serious adverse events was recorded, and further information
was sought if this was not clear (particularly in relation to hospital
admissions and serious adverse events).
Assessment of risk of bias in included studies
One review author (CJC) assessed the included studies for bias
protection (including sequence generation for randomisation, al-
location concealment, blinding of participants and assessors, loss
to follow-up, completeness of outcome assessment and other pos-
sible bias prevention), with assistance from Susan Hansen.
Unit of analysis issues
We confined our analysis to patients with one or more serious
adverse events, rather than the number of events that occurred (as
the latter are not independent when one patient suffers multiple
events).
Assessment of heterogeneity
Heterogeneity was assessed using I2 to indicate how much of the
total heterogeneity found was between, rather than within studies.
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Data synthesis
The outcomes of this review were dichotomous, and we recorded
the number of participants with at least one outcome event by
allocated treated group. Pooled Odds Ratio (OR) and Risk Differ-
ence (RD) were calculated. The Peto Odds Ratio has advantages
when events are rare, as no adjustment for zero cells is required.
This property was more important than potential problems with
unbalanced treatment arms and large effect sizes in view of the
high proportion of zero cells, and therefore the results for seri-
ous adverse events were calculated in RevMan 5.0 using the Peto
method with theMantel-Haenszel method for sensitivity analysis.
Funnel plots were inspected to assess publication bias.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were conducted on the basis of age (adults ver-
sus children), and dose of formoterol (usual dose versus high dose).
Subgroups were compared using tests for interaction (Altman
2003).
Sensitivity analysis
Sensitivity analysis was carried out to assess the impact of the
method used to combine the study events (Risk Difference, Peto
Odds Ratio, and Mantel-Haenszel Odds Ratio). The degree of
bias protection in the study designs was also part of sensitivity
analysis.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
523 abstracts were found from the search of the Cochrane Air-
ways Group Specialised Register of trials in October 2008. For
this review 59 abstracts were identified as potentially relevant,
and of these 48 were subsequently excluded (see Characteristics
of excluded studies) and eleven were included in the review.
Ten further trials were identified primarily from the AstraZeneca
register of controlled trials (Buhl 2003;D5896C00001;Morice
2007; Morice 2008; Peters 2008; SD-039-0714; SD-039-0718;
SD-039-0719; SD-039-0725; SD-039-0726). No additional tri-
als were found from the Novartis web site or the FDA web site. A
submission from Novartis to the FDA in December 2008 also in-
dicated that there were not trials in the Novartis database in which
patients in randomised trials of Foradil had also been randomised
to inhaled corticosteroids (Novartis 2008).
Included studies
The 21 trials included in this review are described in detail in
Characteristics of included studies. There is also a summary of
the daily dose of budesonide and formoterol that was used in
each trial in Table 1. To avoid confusion, all delivered doses have
been converted to an equivalent metered dose (so Symbicort 320/
9 mcg is a delivered dose that is equivalent to a metered dose of
budesonide 400 mcg and formoterol 12 mcg).
Table 1 also indicates whether each study randomised patients
to once or twice daily formoterol, used combined or separate
inhalers and delivered the medication using dry powder inhaler
(DPI) or pressurised metered-dose inhalers (pMDI). Some trials
had more than two arms so featured more than one option in each
of these cases. Since OPTIMA (O’Byrne 2001; O’Byrne 2001a)
and FACET (Pauwels 1997; Pauwels 1997a) randomised patients
into higher and lower doses of budesonide, each has been consid-
ered as two separate comparisons and been given two identifiers.
The review therefore lists a total of 23 studies, drawn from the 21
trials which have been conducted.
All the trials have been sponsored or supported by AstraZeneca.
Adults
A total of 8,028 adults and adolescents were randomised in seven
trials enrolling participants over the age of 12 years (Corren 2007;
Jenkins 2006;Morice 2007;Noonan 2006;D5896C00001; Peters
2008; Price 2002), a further six trials that enrolled adults over the
age of 18 years (Buhl 2003; Chuchalin 2002; Kuna 2006; O’Byrne
2001; Pauwels 1997; Zetterstrom2001) and a single trial enrolling
those over 16 years old (SD-039-0726). All these studies had a
mean age of greater than 18 years.
The weighted mean duration of the adult and adolescent studies
was 31 weeks. The daily metered dose of formoterol used was 12
to 24 mcg, with the exception of Jenkins 2006 and Peters 2008
where 48 mcg daily was used (which remains within the licensed
daily dose range). The daily metered dose of budesonide ranged
from 200 to 1600 mcg (see Table 1).
Children
The seven trials in children include 2788participants in the follow-
ing age ranges: Morice 2008 (6-11 years old), Pohunek 2006 (4-
11), SD-039-0714 (11-17), SD-039-0718 (6-15), SD-039-0719
(6-11), SD-039-0725 (6-15), Tal 2002 (4-17). All these studies
had a mean age of participants of less than 18 years.
Theweightedmeandurationof the children and adolescent studies
was 13 weeks. The daily metered dose of formoterol was 12 to 24
mcg. The daily metered dose of budesonide was 200 to 400 mcg
(see Table 1).
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Risk of bias in included studies
An overview of the risk of bias in individual studies is shown in
Figure 1.
Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Very little information is available from the paper publications or
web reports on sequence generation or allocation concealment,
but this is unlikely to be a source of bias in view of the fact that
all the studies are sponsored, and standard methodology is likely
to have been used to minimise the risk of selection bias.
Blinding
All of the studies were double-blind with the exception of SD-
039-0719, which was an open study.
Incomplete outcome data
The rate of withdrawals and dropouts was clearly reported and was
generally less than 20% of randomised participants, and similarly
in the arms of each study.
Selective reporting
Data have been found or provided from the sponsor for fatal and
non-fatal serious adverse events by treatment group and causation
for all studies except D5896C00001, which is yet to be published
in full and does not include details of asthma-related serious ad-
verse events. With this exception we have therefore obtained data
from all trials in relation to the primary outcomes of all cause
mortality and all cause serious adverse events.
Other potential sources of bias
All studies were sponsored or supported by AstraZeneca, theman-
ufacturer of combined budesonide/formoterol inhalers.
Effects of interventions
Primary Outcomes
All cause mortality
There were no deaths in the trials on children and adolescents
(2,788 participants). In the adult and adolescent studies (8,028
participants), there were four deaths which were all in patients
taking formoterol with inhaled corticosteroids. These trials were
combined using Peto Odds Ratio (as no continuity correction for
zero cells is required). The pooled PetoOdds Ratio was 5.83 (95%
confidence interval 0.78 to 43.77) and I2 was zero Figure 2.When
analysed using risk differences with a fixed effects model the RD
is 0.001 (95% CI -0.001 to 0.003) for adults and adolescents and
the RD is zero (95% CI -0.004 to 0.004) in trials on children and
adolescents (in which there were no deaths) Figure 3.
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Figure 2. Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.1 All-cause
Mortality.
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Figure 3. Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.5 All-cause
Mortality (risk difference)).
The reports of the deaths included one due to cardiac arrest on
combined formoterol and budesonide inhaler treatment (Buhl
2003), one due to status asthmaticus with subsequent develop-
ment of septic shock on separate formoterol and budesonide in-
halers (O’Byrne 2001), one due to suicide on separate formoterol
and budesonide inhalers (Pauwels 1997a) and one due to suicide
on combined formoterol and budesonide inhaler (Zetterstrom
2001). There was one additional death due to pulmonary embolus
on combined treatment in Jenkins 2006, but this death occurred
after the budesonide only control arm was discontinued and all
patients were receiving formoterol, so it has not been included in
the meta-analysis.
Serious Adverse Events (non-fatal all cause)
A serious adverse event is defined as an event that falls in any of
the following categories:
• Results in death,
• Is life-threatening,
• Requires inpatient hospitalization or prolongation of
existing hospitalization,
• Results in persistent or significant disability/incapacity, or
• Is a congenital anomaly/birth defect.
This is further explained in Appendix 3, and the sponsors have
confirmed that this definition was used in the included trials (even
though this was often not made explicit in the paper reports).
All ages
The combined result in all ages was PetoOdds Ratio of 1.06 (95%
CI 0.81 to 1.39) and I2 was 8% (see Figure 4), and the pooled
RD for all ages was 0.001 (95% CI -0.004 to 0.007) Figure 5.
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Figure 4. Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.2 All-cause
non-fatal Serious Adverse Events.
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Figure 5. Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.6 All-cause
non-fatal Serious Adverse Events (risk difference)).
Adults and Adolescents
Thenumber of patients experiencing one ormore non-fatal serious
adverse events was very similar when formoterol was randomised
with inhaled corticosteroids in comparison to inhaled corticos-
teroids alone. There were 116 out of 4875 (2.4%) participants on
regular formoterol with ICS and 86 out of 3153 (2.7%) on ICS
alone in whom such events occurred. The Peto Odds Ratio was
0.99 (95% CI 0.74 to 1.33) and I2 was zero. The pooled RD was
-0.0003 (95% CI -0.007 to 0.007).
Children and Adolescents
In the trials in patients who were less than 18 years of age the
results were more heterogeneous and more non-fatal serious ad-
verse events occurred with formoterol. There were 25 such events
amongst young people out of 1719 (1.5%) on regular formoterol
with ICS and nine out of 1069 (0.8%) on ICS alone. The Peto
Odds Ratio was 1.62 (95% CI 0.80 to 3.28) and I2 was 32%, and
the pooled RD for children was 0.006 (95% CI -0.003 to 0.01).
When Tal 2002 is removed from the analysis, the I2 measurement
is reduced to 0. In this study there were seven children with events
on formoterol and none on ICS alone.
The test for interaction between adults and children did not find
a significant impact of age on the treatment effect.
Secondary Outcomes
Mortality by cause of death
None of the four deaths in adults were reported as being due to
asthma in the original trial reports, but the death in O’Byrne 2001
(OPTIMA) was subsequently attributed to status asthmaticus and
septic shock in a recent meta-analysis (Sears 2008). The full report
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of the cause of death from the sponsors was “One of the deaths
occurred in a 35 year old female after an 8 day hospitalization
for a severe asthma attack leading to intubation, ventilation, and
nosocomial pneumonia with septic shock.” This is the only death
that has been reported as relating to asthma and was in a patient
taking budesonide/formoterol Figure 6. Two deaths were reported
as due to suicide and one as related to cardiac arrest.
Figure 6. Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.3 Asthma
Mortality.
Serious Adverse Events related to Asthma
All Ages
The combined result in all ages was PetoOdds Ratio of 0.68 (95%
CI 0.39 to 1.18) and I2 was 21% Figure 7, and the pooled RD for
all ages was -0.002 (95% CI -0.005 to 0.001) Figure 8.
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Figure 7. Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.4 Asthma-
related non-fatal Serious Adverse Events.
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Figure 8. Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.7 Asthma-
related non-fatal Serious Adverse Events (Risk Difference).
Adults and Adolescents
The number of patients experiencing one or more asthma related
non-fatal serious adverse events was lower when formoterol was
randomised with inhaled corticosteroids in comparison to inhaled
corticosteroids alone, but the result was statistically significant
using Peto Odds Ratio but not Risk Difference. There were 15
out of 4875 (0.3%) participants on regular formoterol with ICS
and 24 out of 3153 (0.8%) on ICS alone. The Peto Odds Ratio
was 0.53 (95% CI 0.28 to 1.00) and I2 was zero. The pooled RD
was -0.003 (95% CI -0.007 to 0.0005).
Children and Adolescents
In the trials in patients who were less than 18 years of age the
results were againmore heterogeneous. There were 9 young people
out of 1719 (0.5%) on regular formoterol with ICS and four out
of 1069 (0.4%) on ICS alone. The Peto Odds Ratio showed a
non-significant increase at 1.49 (95% CI 0.48 to 4.61) and I2 was
60%. The pooled RD was 0.002 (95% CI -0.005 to 0.009).
The difference between children and adults was again not statisti-
cally significant. We did not find sufficient data to assess the other
proposed secondary outcomes (such as ITU admission and in-
tubation). There was one intubation (inhaled corticosteroid only
group, O’Byrne 2001).
Sensitivity Analyses
Risk of bias
No deaths occurred in the unblinded study in children (SD-039-
0719) so exclusion of this study made no difference to mortality
outcomes. When this study was excluded for non fatal serious
adverse events, the Peto Odds Ratio for children was 1.69 (95%
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CI 0.81 to 3.54) and I2 was 45% Figure 9. A funnel plot did not
suggest obvious publication bias Figure 10.
Figure 9. Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.10 All-cause
non-fatal Serious Adverse Events (sensitivity analysis without unblinded study).
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Figure 10. Funnel plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.2 All-cause
non-fatal Serious Adverse Events.
Methods of analysis
The primary outcomes were also analysed using Mantel-Haenszel
fixed and random effects models. The results of the fixed effects
model for mortality are shown in Figure 11. This method uses a
correction for zero cells whichmeans that the pooledOR is smaller
than the Peto OR, since the addition of 0.5 to all cells when the
arms have similar numbers randomised will generate an OR of 3
when there is only one event.When there are very sparse outcomes
(such as for mortality), the results are entirely dependent on the
size of the zero cell adjustment, and whether the treatment arms
are balanced. For serious adverse events theMantel-Haenszel fixed
and random effectsmodels gave almost identical results to the Peto
method Figure 12.
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Figure 11. Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.8 All-cause
Mortality.
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Figure 12. Forest plot of comparison: 1 Formoterol and ICS versus same dose ICS, outcome: 1.9 All-cause
non-fatal Serious Adverse Events.
Dose of formoterol
The dose of formoterol used in all studies was within the licensed
daily dose, so no sensitivity analysis was required to exclude unli-
censed doses.
Subgroup Analyses
Mortality data were too sparse to carry out any sub-group analysis.
Although the results for adults and children showed trends in
opposite directions for non fatal serious adverse events (both all-
cause and asthma-related), the test for interaction did not show a
significant interaction of treatment effect and age.
D I S C U S S I O N
Summary of main results
All cause mortality
The confidence intervals for all cause mortality in adults indicate
that for every thousand patients treated with regular formoterol
and inhaled corticosteroids in comparison to inhaled corticos-
teroids alone we can expect something between three additional
deaths and one less death in adults over 31 weeks of treatment,
and at most four additional deaths to four less deaths in children
over 13 weeks of treatment (the average duration of treatment in
the respective trials). The pooled Peto Odds Ratio for adults was
5.83 (95% confidence interval 0.78 to 43.77), and could not be
calculated for children as there were no deaths in children.
All cause non fatal serious adverse events
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For non-fatal serious adverse events the limits of the pooled confi-
dence interval are seven more to seven fewer adults and ten more
to three fewer children for every thousand treated over the period
of time represented in the trials. The Peto Odds Ratio was 0.99
(95% CI 0.74 to 1.33) for adults, and 1.62 (95% CI 0.80 to 3.28)
for children with heterogeneity present for the results of the stud-
ies in children.
Overall completeness and applicability of
evidence
Two large studies have been carried out on the use of regular salme-
terol (SMART 2006, SNS 1993), but the only large surveillance
study on formoterol Pauwels 2003 (RELIEF) investigated its use
as a reliever rather than as maintenance therapy and has therefore
not been included in this review. This means that there is less data
in this review to investigate the impact of formoterol on serious
adverse events in comparison to our previous review on salmeterol
(Cates 2008).
The small numbers of events in this review results in low precision
of the estimates of relative risk between formoterol and control.
However, outcome data were obtained from all the included stud-
ies and a funnel plot did not suggest publication bias.
Quality of the evidence
Risks of bias in the studies included in this review are thought to
be low, as almost all the studies were double blind, and although
allocation concealment was not well reported, it is likely to have
been adequate as all the trials were sponsored or supported by As-
traZeneca. Since the trials were carried out for regulatory purposes
the collection of serious adverse event data will have been assessed
using uniform definitions across the studies.
The level of heterogeneity within the subgroup of paediatric trials
is significant (I2 = 60%), and cannot be explained easily. The
confidence intervals from two studies do not overlap (Morice
2008; Tal 2002), with the observed results indicating protection
(Morice 2008), and harm (Tal 2002).
Potential biases in the review process
The selection of the best method to combine studies with rare
events is contentious when event rates are low, not least because of
the corrections required to calculate Odds Ratios with zero events
(Sweeting 2004). Since it became apparent in the course of the
review that the pooled odds ratios were heavily dependent on the
zero adjustment used in theMantel-Haenszel and Inverse variance
methods, we used the Peto Odds Ratio and risk differences to
report results of this review. Since the imbalance between the trial
arms is never more than two to one the likely bias in using the
Peto Odds Ratio is small (Sweeting 2004).
Similarly the included studies were influenced by the decision to
restrict the review to trials that randomised participants to for-
moterol and inhaled corticosteroids, but this decision reduces the
risk of bias arising from patients discontinuing their usual inhaled
steroid medication if they feel better on the randomised treat-
ment. This presupposes a similar risk of SAEs when formoterol
and budesonide are delivered via one inhaler, and when formoterol
is introduced to ICS therapy via a separate inhaler, when both are
randomised treatments in a controlled trial.
Agreements and disagreements with other
studies or reviews
Mortality
Comparing the results from this review and the review on regu-
lar formoterol without randomised inhaled corticosteroids (Cates
2008a) indicates that all 7 deaths in the trials comparing for-
moterol to placebo or comparing formoterol with ICS to the same
dose of ICS were in patients who were randomised to formoterol
(with or without ICS), see Figure 13. This is a cause for concern,
because although it may seem that many of the deaths were not
related to asthma, it is often hard to be sure of the exact cause of
death, and the classification of cause of death is not straightfor-
ward. For example the patient who died in OPTIMA (O’Byrne
2001) was recorded in the paper as dying from septic shock, but
listed in Sears 2008 as status asthmaticus and septic shock, whereas
the 13 year old boy who died in Von Berg 2003 is listed in Sears
2008 as dying of respiratory failure but the paper has reported that
the cause of deathwas subarachnoid haemorrhage. Sears 2008 does
not report all-cause mortality in the sub-group of trials in patients
on regular formoterol and maintenance ICS; the primary analysis
on all-cause mortality include the RELIEF study which allowed
regular long-acting beta2-agonists in both arms and therefore was
not included in this review. The adjusted all-cause mortality in
Sears 2008 is RR 1.79 (95% CI 0.80, 4.00) when studies with any
baseline ICS are considered; the conditional logistic regression was
adjusted for trial effect (data on file provided by AstraZeneca).
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Figure 13. All cause mortality in trials of regular formoterol with or without ICS
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Only one asthma related death was reported in this review, but
the overview of Sears 2008 identified two further asthma-related
deaths from the AstraZeneca database of trials in which partici-
pants were on maintenance ICS; all three deaths were in partici-
pants randomised to regular formoterol.
There were 6 additional death when formoterol and inhaled corti-
costeroids were compared to higher dose of inhaled corticosteroids
- three deaths in each arm (Jaeschke 2008).
We agree with the conclusion of Sears 2008 that “the power is
insufficient to conclude no increased mortality with formoterol”
when regular formoterol is used in conjunction with ICS.
All-cause non fatal serious adverse events
Sears 2008 does not present data on all-cause serious adverse
events, but Jaeschke 2008 has also found that the reduction in
asthma-related serious adverse events and hospitalisations do not
seem to translate into similar reductions in all-cause serious ad-
verse events (which are about four times more common). Jaeschke
2008 and Jaeschke 2008a did not include trials in children. There
is insufficient information from the trials in children in this re-
view to determine whether the increased risk of non-fatal serious
adverse events found on formoterol alone found in Cates 2008a
(PetoOR 2.48; 95%CI 1.27 to 4.83), is abolished by the addition
of randomised inhaled corticosteroids (Peto OR 1.62; 95% CI
0.80 to 3.28), as there is a large degree of overlap in the confidence
intervals leading to a negative test for interaction, see Figure 14.
Figure 14. All cause serious adverse events in children on regular formoterol (with or without ICS)
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is not possible, from the data in this review, to reassure people
with asthma that regular use of inhaled corticosteroids with for-
moterol carries no risk of increasing mortality in comparison to
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inhaled corticosteroids alone as all four deaths occurred among
6,594 people using both drugs. On the other hand we have found
no conclusive evidence of harm and there was only one asthma re-
lated death registered during over 3,000 patient years observation
on formoterol. In adults, the decrease in asthma-related serious
adverse events on regular formoterol with inhaled corticosteroids
was not accompanied by a similar decrease in all cause serious ad-
verse events. In children the number of events was too small to de-
termine whether the increase in all cause non-fatal serious adverse
events previously found on regular formoterol alone is abolished
by the additional use of inhaled corticosteroids. Clinical decisions
and information for patients regarding regular use of formoterol
have to take into account the balance betweenknown symptomatic
benefits of formoterol and the degree of uncertainty and concern
associated with its potential harmful effects.
Implications for research
Future research should clearly specify the number of patients with
fatal and non-fatal serious adverse events by treatment group and
cause. Any new surveillance study to investigate the impact of reg-
ular formoterol and inhaled corticosteroids on all-cause mortality
would need to be very large.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Buhl 2003
Methods Study Design: A randomised, double-blind, double-dummy, active-controlled, Mul-
ticentre, parallel-group study over 12 weeks from October 1999 to June 2000 at 56
centres in 9 countries. (Argentina (5), Belgium (5), the Czech Republic (14), Germany
(6), Mexico (4), Russia (6), Spain (5), the Netherlands (7) and United Kingdom (4))
Run-in 2 weeks (budesonide 200 mcg twice daily)
Participants Population: 523 adults (18-78) years with moderate persistent asthma.
Baseline Characteristics: Mean age 44 years. FEV1 77% predicted. Concomitant in-
haled corticosteroids used by 100% of participants (400-1000 mcg/day) and patients
not fully controlled on this dose
Inclusion Criteria:Out-patients aged 18 years and older with perennial asthma (ATS)
with a minimum duration of 6 months. Used any inhaled corticosteroid at a constant
daily dose of 400-1000 µg for at least 30 days before entry and still had sub-optimal
asthma control. FEV1 % predicted between 60% to 90%, bronchodilator reversibility
by an increase of at least 12% in FEV1 over baseline at 15 minutes after inhalation of a
short-acting beta2-agonist
Exclusion Criteria: Use of oral, parental or rectal GCS within 30 days prior to visit
1, seasonal asthma, significant respiratory infection within 30 days of visit 1, severe
cardiovascular disorder or any other significant disease or disorder, pregnant or planning
a pregnancy, breast-feeding, not using acceptable contraceptives, not surgically sterile,
hypersensitivity to study drugs, tobacco smokers or previous smokers if greater than 10
pack-years
Interventions 1. Budesonide/Formoterol 320/9 µg daily
2. Budesonide/Formoterol 160/4.5 µg twice daily
3. Budesonide 400 µg daily (equivalent daily dose of budesonide)
Delivery was DPI
Outcomes The primary efficacy variable was morning peak expiratory flow (am PEF, L/min)
Paper reports five SAEs: one in the once daily BDF group and two each in the other
groups. They included one death due to cardiac arrest and four other events. (No details
given by treatment group in paper or on web report)
Jaeschke 2008 reports one death on combined treatment and two participants with
non-fatal SAE on combined treatment and two on budesonide. One SAE on BDF was
asthma-related
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
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Buhl 2003 (Continued)
Allocation concealment? Unclear Not reported
Blinding?
All outcomes
Yes Double-blind
Incomplete outcome data addressed?
All outcomes
Yes 480/523 (92%) completed the study
Free of selective reporting? Yes SAE data not attributable to treatment
groups in paper but obtained from Jaeschke
2008
Chuchalin 2002
Methods Study Design: A randomised, double-blind, parallel-group study over 12 weeks in
Russia. Run-in 2 weeks
Participants Population: 338adults (18- 66) years with mild to moderate asthma.
Baseline Characteristics:Mean age 45 years. FEV1 unknown%predicted. Concomitant
inhaled corticosteroids used by 0% of participants.
Inclusion Criteria:Diagnosed at least 6 months. FEV1 % predicted between 50% and
85%, bronchodilator reversibility at least 15% in FEV1 over baseline after inhalation of
terbutaline. Female patients to be postmenopausal, surgically sterile or using medically
approved contraceptive measures.
Exclusion Criteria: smoking history of greater than 10 pack-years, current or recent users
of inhaled, oral or parenteral corticosteroids, oral leukotriene antagonists, nedocromil
sodium or sodium cromoglycate, beta-blockers (including eye drops)
Interventions 1. Budesonide and Formoterol 200 and 9 µg BD
2. Budesonide 200 µg BD
Delivery was DPI
Outcomes The primary efficacy variable was the change in peak expiratory flow (PEF) in the
morning before any study medication was taken
Paper reports no deaths and two serious adverse events (aggravated asthma and hyper-
tension) that required hospitalisation in the budesonide only group
Notes Supported by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear “Allocated a randomised number (identi-
fying which of the three treatments they
would receive) in consecutive order, per
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Chuchalin 2002 (Continued)
centre, at the second visit”
Blinding?
All outcomes
Yes Double-blind
Incomplete outcome data addressed?
All outcomes
Yes 316/338 (93%) completed the study.
Free of selective reporting? Yes SAE data reported in the paper
Corren 2007
Methods Randomized, double-blind, double-dummy, multicenter, placebo-controlled study over
12 weeks at 56 US centres from July 2002 to September 2003. Run-in 7-21 days in
which usual asthma therapy was withdrawn
Participants Population: 480 adolescents and adults (12- 78) years with mild to moderate persistent
asthma. 123 randomised to BDF and 121 to Budesonide. The web report also includes a
further 13 children in these treatment groups aged 6-11 years, but they are not separately
analysed
Baseline Characteristics: Mean age 36 years. FEV1 75% predicted. Concomitant in-
haled corticosteroids used by 100% of participants at baseline but withdrawn for the
formoterol and placebo arms of this study
Inclusion Criteria: Mild to moderate persistent asthma for at least 6 months, treated
with inhaled corticosteroids for at least 4 weeks before screening, FEV1 between 60%
and 90% predicted on ICS at screening and between 50% and 85% predicted after
discontinuation of ICS during run-in period. Bronchodilator reversibility of at least
12% and 0.20 L in FEV1 over baseline within 15 to 30 minutes after administration of
albuterol pMDI (2-4 inhalations [90 µg per inhalation])
Exclusion Criteria: Reasons for exclusion from the study included severe
asthma (as judged by the investigator), asthma requiring hospitalization once or emer-
gency treatment more than once within the 6 months before the study or requiring
treatment with systemic corticosteroids within the 4 weeks before screening, and/or a
>10-pack-year smoking history at screening. Pregnant or breastfeeding
Interventions 1. Budesonide/Formoterol 160/9 µg (DPI) twice daily
2. Budesonide 160 µg (DPI) twice daily
The Symbicort and Budesonide arms of this study are included in this review
Outcomes The co-primary efficacy variables were changes from baseline in morning predose FEV1
and 12-hour mean FEV1 (from serial spirometry) after administration of the morning
dose of study medication
Two serious adverse events in the BDF group (lobar pneumonia and facial bone fracture)
reported in the paper. No cardiac related serious adverse events were reported in any
group. No deaths occurred in any group (web site data)
Jaeschke 2008 reports no asthma related SAE events.
Notes Study sponsored by AstraZeneca.
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Corren 2007 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes By study site, computer-generated alloca-
tion schedule using balanced blocks of 4
Allocation concealment? Unclear No information
Blinding?
All outcomes
Yes Double dummy. Patients received both a
pMDI and DPI containing either active
treatment or placebo of the alternative ac-
tive treatment as appropriate
Incomplete outcome data addressed?
All outcomes
Yes 18/123 discontinued on BDF and 18/121
Budesonide
Free of selective reporting? Yes Serious Adverse Events reported in paper
publication
D5896C00001
Methods Study Design:A randomised, double-blind, single-dummy, active-controlled, multicen-
ter, parallel-group study over 12 weeks from October 2003 to February 2005 at 143
centres in the United States. Run-in 4-5 weeks
Participants Population: 619 adolescents and adults (12- 79) years with asthma.
Baseline Characteristics: Mean age 35 years. FEV1 76% predicted. Concomitant in-
haled corticosteroids used by 100% of participants.
Inclusion Criteria: 12 years of age and older, had a documented clinical diagnosis of
asthma for at least 6months prior to screening, and who were in stable condition. Should
have received maintenance asthma treatment with inhaled corticosteroids (ICS) for at
least 4 weeks prior to the screening visit. FEV1 % predicted between 60% and 90%
measured at least 24 hours after the last dose of long-acting B2-agonist and 6 hours after
the last dose of short-acting B2-agonist.
Interventions 1. Budesonide/Formoterol 160/4.5 µg 2x QD pMDI
2. Budesonide/Formoterol 80/4.5 µg 2x QD pMDI (data not used from this arm)
3. Budesonide/Formoterol 80/4.5 µg 2x BD pMDI
4. Budesonide 160 µg 2x QD pMDI
Outcomes Primary variable: evening predose FEV1.
No full paper publication for this study. Web report indicated 2 SAE on BDF 160/4.5
twice daily with a further patient who had a myocardial infarction on the day after the
treatment was discontinued. No deaths occurred. No data on asthma SAEs found
Notes Sponsored by AstraZeneca
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Not reported
Blinding?
All outcomes
Yes Double-blind. To maintain blinding with
the twice-daily dosing regimen, all subjects
randomised to receive once-daily dosing
were to take the active treatment in the
evening and a matched placebo device in
the morning
Incomplete outcome data addressed?
All outcomes
Yes 12% drop out in each arm
Free of selective reporting? Unclear No asthma-related SAE data found
Jenkins 2006
Methods Study Design: A randomised, double-blind, double-dummy, reference -controlled,
Multicentre, parallel-group study over 24 weeks from July 2001 to June 2002 at 54
centres in 6 countries. (Australia (11), Austria (6) CzechRepublic (15), France(9), Poland
(8) Spain (5)) Run-in 2 weeks (on usual ICS)
Participants Population: 456 adolescents and adults (12-79) years with persistent symptomatic
asthma.
Baseline Characteristics:Mean age 46 years. FEV1 66%predicted.Concomitant inhaled
corticosteroids used by 100% of participants.
Inclusion Criteria:Out-patients aged 12 years and older with a diagnosis of asthma
(minimum duration 6 months) FEV1 % predicted between 40?85%, bronchodilator
reversibility by an increase of at least 15% in FEV1 over baseline after inhalation of a
bronchodilator. For patients aged 18 years and older, an increase in baseline FEV1 of at
least 200 mL 15 to 30 min post bronchodilator was required at study entry (visit 1). All
patients had used ICS for at least 4 months at a constant daily dose of at least 750 mcg
for at least 4 weeks before study entry.
Exclusion Criteria:If asthma deteriorated, resulting in a change of asthma therapy. Total
asthma symptom score had to be >1 on a scale of 0?6 for at least 4 of the last 7 days of
run-in. The total asthma symptom score was the sum of daytime and night-time asthma
symptom scores, each measured on a scale of 0-3 (where 0 = no symptoms and 3 = unable
to perform usual activities (or to sleep) because of asthma)
Interventions 1. Budesonide/Formoterol 320/9 µg two inhalations BD + Placebo BD
2. Budesonide 400 µg two inhalations BD + Formoterol 9 µg two inhalations BD +
Placebo BD
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3. Budesonide 400 µg two inhalations BD + Placebo BD
This was the treatment for the first twelve weeks, then group three was split between the
first two treatments. DPI delivery
Outcomes The primary efficacy variable was morning PeakExpiratory Flow (PEF) as registered daily
in diary cards
Paper reports 5 patients with SAE on BDF and two on Budesonide. One death occurred
in the BDF group from Pulmonary Embolism, but as this was after 17 weeks when there
was no budesonide control arm, this has not been included in the meta-analysis
Data from AstraZeneca shows 7 patients with SAE on BDF and 3 on Budesonide in the
first 12 weeks of the study. This has been used in the meta-analysis. It is not clear why
the paper reports different numbers
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Individual treatment codes were computer
generated in balanced blocks of 8 at As-
traZeneca R&D, Lund, Sweden
Allocation concealment? Yes codes were then assigned to patients and
kept in sealed envelopes until data analysis
Blinding?
All outcomes
Yes Double-blind
Incomplete outcome data addressed?
All outcomes
Yes 400/456 (88%) completed the study
Free of selective reporting? Yes SAE data in paper, but this did not match
final data from sponsors
Kuna 2006
Methods Study design: A randomised, double-blind, double-dummy, active-controlled, Multi-
centre, parallel-group study over 12 weeks fromNovember 1999 to July 2000 at 60 cen-
tres in 8 countries. (Finland (5), Germany (17), Mexico (4), New Zealand (3) Norway
(6), Poland (7), Russia (5), Sweden (13) Run-in 2 weeks in which all patients received
budesonide 200 mcg daily (half the previous average dose)
Participants Population: 616 adults (18-80) years with mild to moderate persistent asthma.
Baseline Characteristics: Mean age 45 years. FEV1 78.5% predicted. Concomitant
inhaled corticosteroids used by 100% of participants.
Inclusion Criteria: 18 years of age and older, a diagnosis of asthma (minimum duration:
6 months) that was not optimally controlled despite a daily ICS dose of 200 to 500 mg
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for at least 30 days before study entry. FEV1 % predicted of 60 to 90%, bronchodilator
reversibility by an increase of at least 12% in FEV1 over baseline after inhalation of either
1mg of terbutaline or salbutamol 0.4 mg.
Exclusion Criteria: used any systemic corticosteroids within the previous 30 days; sea-
sonal asthma (defined as asthma exacerbated by seasonal increases in aero allergens); a
respiratory infection in the 4 weeks before study entry; a severe cardiovascular disorder
or any other significant disease; used ß-blocker therapy (including eye drops) or had a
history of heavy smoking (X10 pack-years), women of child-bearing potential who were
pregnant or who failed to use acceptable contraceptive measures,
Interventions 1. Budesonide/Formoterol 80/4.5 µg 2x QD
2. Budesonide/Formoterol 80/4.5 µg BD
3. Budesonide 200 µg QD
Delivery was DPI and all arms received equivalent delivered dose of 160 mcg budesonide
daily
Outcomes The primary variable was morning PEF.
“Seven serious adverse events were reported:two in the once daily BDF group, one in the
twice daily BDF group and four in the budesonide group.” Although the three asthma
SAEs were not described by treatment group in the paper or the web report, Jaeschke
2008 indicates one on BDF and two events on budesonide, with one hospitalisation for
asthma in each group. No mortality
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not described
Allocation concealment? Unclear Not described
Blinding?
All outcomes
Yes To ensure treatment blinding, a double-
dummy design was used so that patients
received four successively numbered Tur-
buhalers, with the corresponding placebo
inhalers being identical in appearance to
those containing active medication
Incomplete outcome data addressed?
All outcomes
Yes 555/616 (90%) completed the study
Free of selective reporting? Yes SAE reported in paper by treatment group
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Morice 2007
Methods Study Design: A randomised, double-blind, double-dummy, parallel-group study over
12 weeks from April
2002 to February 2003 at 62 centres in Brazil (7), Bulgaria (5), Canada (9), Hungary
(9), Mexico (7), the Philippines (6), Thailand (5), UK (14)). Run-in 2 weeks on pre-
study ICS but LABA was withdrawn from the 15% previously treated with LABA and
ICS
Participants Population: 680 adolescents and adults (12 - 79) years with asthma.
Baseline Characteristics: Mean age 40 years. FEV1 70% predicted. Concomitant in-
haled corticosteroids used previously by 100% of participants (mean dose 770 mcg/day)
.
Inclusion Criteria: 12 years of age and older with asthma for at least 6 months, who
were inadequately controlled on ICS alone, FEV1 % predicted between 50% and 90%,
bronchodilator reversibility by an increase of at least 12% in FEV1 after inhalation of
terbutaline 1 mg, a history of daily ICS use (stable dose of 500?1600 mcg/day within 30
days prior to enrolment) for at least 3 months. Symptoms must have been present on at
least 4 of the last 7 days of run-in
Exclusion Criteria: not defined
Interventions 1. Budesonide 200 µg 2x BD pMDI (CFC propellant)
2. Budesonide/Formoterol 160/4.5 µg 2x BD DPI
3. Budesonide/Formoterol 160/4.5 µg 2x BD pMDI (HFA propellant)
All delivered the same daily dose of budesonide
Outcomes The primary efficacy end-point was the change in morning peak expiratory flow (PEF)
from baseline (mean of the last 10 days of run-in) to the mean value over the 12-week
treatment period
Paper report: “No deaths occurred. Four subjects experienced serious adverse events, two
in the budesonide group (joint dislocation, asthma) and two in BDF pMDI (menorrha-
gia, increased liver enzymes).”
Notes Sponsored by AstraZeneca.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were randomised sequentially in
blocks of six using a computer-generated
randomisation schedule
Allocation concealment? Yes Eligible patients were consecutively allo-
cated the lowest available randomisation
code. In view of double-dummy design this
is considered satisfactory
Blinding?
All outcomes
Yes Double-blind, double-dummy. To main-
tain blinding, each patient also received a
placebo device
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Incomplete outcome data addressed?
All outcomes
Yes 600/680 (88%) completed the study
Free of selective reporting? Yes Full SAE data available frompaper by treat-
ment group and cause
Morice 2008
Methods Study Design: A randomised, double-blind, double-dummy, parallel-group study over
12weeks from June 2002 toMay 2003 at 53 centres inArgentina (4), Brazil (6),Denmark
(14), Hong Kong (1), Mexico (6), Poland (4), Slovakia (12), and Taiwan (6))
Run-in 2 weeks on previous ICS dose (but previous LABA may have been withdrawn ?
not made clear in the paper)
Participants Population: 622 children (6- 11) years with symptomatic asthma.
Baseline Characteristics:Mean age 8 years. FEV1 82%predicted. Concomitant inhaled
corticosteroids used by 100% of participants (375 to 100 mcg daily).
Inclusion Criteria: Paediatric out-patients (6-11 years) with asthma and a history of
clinically important exercise-induced bronchoconstriction, daily using 375-1000 µg of
inhaled glucocorticosteroids (GCSs), peak expiratory flow (PEF) at least 50% of pre-
dicted normal value (pre bronchodilator). Had to have a total asthma-symptom score
(night-time plus daytime) of at least 1 on at least 4 of the last 7 days of the run-in period
and a mean morning PEF (mPEF) during the last 7 days of the run-in period of 50-85%
of post bronchodilatory PEF, measured at Visit 1 (enrolment).
Exclusion Criteria: inability to use DPI and Peak Flow meter.
Interventions 1. Budesonide 100 µg 2x BD pMDI
2. Budesonide/Formoterol 80/4.5 µg 2x BD DPI
3. Budesonide/Formoterol 80/4.5 µg 2x BD pMDI
Dose of budesonide was equivalent in each arm (100 metered dose equivalent to 160
delivered dose)
Outcomes The primary efficacy end-point was the change in morning peak expiratory flow (PEF)
from baseline (mean of the last 10 days of run-in) to the mean value over the 12-week
treatment period
Paper reports: “Five patients reported serious adverse events: 3 in budesonide group
(asthma aggravation (2), nervousness), 2 BDFDPI (acute sinusitis, migraine). No deaths
were reported.”
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were randomised sequentially in
blocks of six using a computer-generated
randomisation schedule
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Allocation concealment? Unclear No details
Blinding?
All outcomes
Yes Double blind (all patients used a placebo
inhaler and an active inhaler)
Incomplete outcome data addressed?
All outcomes
Yes 583/622 (94%) completed the study
Free of selective reporting? Yes SAE reported by treatment group and cause
in paper
Noonan 2006
Methods Randomized, double-blind, double-dummy, multicenter, placebo-controlled study over
12weeks from July 2002 to January 2004 at 84US centres (respiratory or allergy speciality
clinical practice) Run-in 2 weeks
Participants Population: 596 adolescents and adults (12-87) years with moderate to severe persistent
asthma. BDF 124 patients, BD + F 115 patients, Budesonide 109 patients
Baseline Characteristics: Mean age 41 years. FEV1 67% predicted. Concomitant in-
haled corticosteroids used by 100% of participants.
Inclusion Criteria: Moderate to severe persistent asthma chronically treated with a
medium to high dose of ICS, FEV1 %predicted within the entrance range of 45% to
85%, bronchodilator reversibility of FEV1 of at least 12% and 0.20 L from the pre-
albuterol baseline value within 15 to 30 minutes after administration of a standard dose
of salbutamol.
Exclusion Criteria: Requiring hospitalisation once or emergency treatment more than
once in the preceding 6 months, greater than 10-pack-per-year smoking history
Interventions 1. Budesonide 160 mcg twice daily
2. Budesonide/Formoterol 160/9 mcg pMDI twice daily
3. Budesonide pMDI and Formoterol DPI 160/9 mcg twice daily
Outcomes The co-primary efficacy variables were baseline adjusted average 12-hour FEV I and
predose FEV I.
“Nine subjects had SAEs during double-blind treatment: 4 on BDF pMDI (asthma -2,
urti and ECG T wave inversion), 2 in the formoterol group and 3 in the budesonide +
formoterol group (small intestine obstruction, abdominal injury, pneumonia).”
Web data found on AZ clinical trials web site SD-039-0717
Notes Sponsored by AstraZeneca. Jaeschke 2008 excluded this study as there were more than
20% dropouts.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated allocation schedule
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Allocation concealment? Yes Identical packages shipped to centres
Blinding?
All outcomes
Yes Double blind
Incomplete outcome data addressed?
All outcomes
Yes 23% withdrawals in combined arms and
28% in budesonide arm
Free of selective reporting? Yes Full SAE data on web site
O’Byrne 2001
Methods Study design: A randomised, double-blind, parallel-group study over 12 months from
January 1998 to February 2000 at 198 centres in 17 countries. Run-in 1 month
Participants Population: 1970 adults (18-76) years with mild asthma, (Group A - 698) and mild-
to-moderate asthma (Group B - 1,272)
Baseline Characteristics:
(Group A) Mean age 31 years. FEV1 90% predicted. Concomitant inhaled corticos-
teroids used by 0% of participants.
(GroupB)Mean age 37 years. FEV1 87%predicted.Concomitant inhaled corticosteroids
used by 100% of participants.
Inclusion Criteria: 12 years of age and older. Diagnosis of stable asthma, according to
the American Thoracic Society (ATS).
(Group A) had used no inhaled corticosteroid for at least 3 months, pre-bronchodilator
FEV1 %predicted at least 70% at visit 1. 15 min post bronchodilator FEV1 %predicted
at least 80% at visit 1 (2x0.5 mg Bricanyl Turbuhaler).
(Group B) taking no more than 400 µg of inhaled budesonide or its equivalent
for at least 3 months, pre-bronchodilator FEV1 % predicted at least 50% at visit 1. 15
min post bronchodilator FEV1 % predicted at least 70% at visit 1 (2x0.5 mg Bricanyl
Turbuhaler).
Exclusion Criteria: use of oralGCSwithin 3months prior to visit 1, beta-blocker therapy
(eyedrops included).pregnant and/or lactating women or women not using acceptable
contraceptives as judged by the investigator, patients with a history of smoking more
than 15 pack-years
Interventions THIS REPORTRELATES TO PATIENTS GIVEN 200 mcg Budesonide twice daily
(Group A)
1. Budesonide 200 µg
2. Budesonide and Formoterol 200 and 4.5 µg
Placebo arm from Group A was not included in this review
(Group B)
1. Budesonide 200 µg
2. Budesonide and Formoterol 200 and 4.5 µg
3. Budesonide 400 µg
4. Budesonide and Formoterol 400 and 4.5 µg
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Outcomes Primary variable was time to first severe asthma exacerbation, expressed as the risk for a
first severe exacerbation, and rate (proportion) of poorly controlled days
Serious Adverse Events are not mentioned at all in the paper publication and the web
report (SD-037-0345) only gives total numbers of patients with SAEs for Group A and
B (with no indication of treatment group)
AstraZeneca have provided a breakdown of all-cause SAE and asthma-related SAE (As-
traZeneca Data on file 2008)
There was one death that was not reported in the paper, but mentioned in the web
report as probably due to ’septic shock’ in group A. Sears 2008 indicates that the death
was also related to status asthmaticus and was in a patient taking budesonide/formoterol
combination treatment. The full report of the death from the sponsors is: “One of the
deaths occurred in a 35 year old female after an 8 day hospitalization for a severe asthma
attack leading to intubation, ventilation, and nosocomial pneumonia with septic shock.
”
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated random numbers
Allocation concealment? Yes Opaque consecutive numbered envelopes
containing assignment
Blinding?
All outcomes
Yes Double-blind. Identical placebo
Incomplete outcome data addressed?
All outcomes
Yes 81% in Group A and 87% in Group B
completed the study
Free of selective reporting? Yes SAE data provided by sponsors and found
from other sources
O’Byrne 2001a
Methods Study design: A randomised, double-blind, parallel-group study over 12 months from
January 1998 to February 2000 at 198 centres in 17 countries. Run-in 1 month
Participants Population: 1970adults (18-76) years with mild asthma, (Group A - 698) and mild-
to-moderate asthma (Group B - 1,272)
Baseline Characteristics:
(Group A) Mean age 31 years. FEV1 90% predicted. Concomitant inhaled corticos-
teroids used by 0% of participants.
(GroupB)Mean age 37 years. FEV1 87%predicted.Concomitant inhaled corticosteroids
used by 100% of participants.
Inclusion Criteria: 12 years of age and older. Diagnosis of stable asthma, according to
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the American Thoracic Society (ATS).
(Group A) had used no inhaled corticosteroid for at least 3 months, pre-bronchodilator
FEV1 %predicted at least 70% at visit 1. 15 min post bronchodilator FEV1 %predicted
at least 80% at visit 1 (2x0.5 mg Bricanyl Turbuhaler).
(Group B) taking no more than 400 µg of inhaled budesonide or its equivalent
for at least 3 months, pre-bronchodilator FEV1 % predicted at least 50% at visit 1. 15
min post bronchodilator FEV1 % predicted at least 70% at visit 1 (2x0.5 mg Bricanyl
Turbuhaler).
Exclusion Criteria: use of oralGCSwithin 3months prior to visit 1, beta-blocker therapy
(eyedrops included).pregnant and/or lactating women or women not using acceptable
contraceptives as judged by the investigator, patients with a history of smoking more
than 15 pack-years
Interventions THIS REPORT RELATES TO PATIENTS GIVEN 400 mcg Budesonide twice daily
(Group A)
1. Budesonide 200 µg
2. Budesonide and Formoterol 200 and 4.5 µg
Placebo arm from Group A was not included in this review
(Group B)
1. Budesonide 200 µg
2. Budesonide and Formoterol 200 and 4.5 µg
3. Budesonide 400 µg
4. Budesonide and Formoterol 400 and 4.5 µg
Outcomes The primary variable was time to first severe asthma exacerbation, expressed as the risk
for a first severe exacerbation, and rate (proportion) of poorly controlled days
Serious Adverse Events are not mentioned at all in the paper publication and the web
report (SD-037-0345) only gives total numbers of patients with SAEs for Group A and
B (with no indication of treatment group)
AstraZeneca have provided a breakdown of all-cause SAE and asthma-related SAEwhich
has been used in the meta-analysis. (AstraZeneca Data on file 2008)
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated random numbers
Allocation concealment? Yes Opaque consecutive numbered envelopes
containing assignment
Blinding?
All outcomes
Yes Double-blind. Identical placebo
Incomplete outcome data addressed?
All outcomes
Yes 81% in Group A and 87% in Group B
completed the study
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Free of selective reporting? Yes SAE data provided by sponsors
Pauwels 1997
Methods Study Design:A randomised, double-blind, Multicentre, parallel-group study over 12
months at 71 centres in 9 countries. (Belgium, Canada, the Netherlands, Israel, Italy,
Luxembourg, Norway, Spain and the United Kingdom). Run-in 4 weeks on 800 mcg
twice daily
Participants Study Design: A randomised, double-blind, Multicentre, parallel-group study over 12
months at 71 centres in 9 countries. (Belgium, Canada, the Netherlands, Israel, Italy,
Luxembourg, Norway, Spain and the United Kingdom) Run-in 4 weeks on 800 mcg
twice daily.
Population: 852 adults (18-70) years with persistent symptomatic asthma.
Baseline Characteristics: Mean age 42 years. FEV1 76% predicted. Concomitant in-
haled corticosteroids used by 100% of participants (mean dose 820 mcg/day).
Inclusion Criteria: 18 to 70 years old, who had had asthma for at least six months
and had been treated with an inhaled glucocorticoid for at least three months. FEV1 %
predicted at least 50 %, bronchodilator reversibility by an increase of at least 15% in
FEV1 over baseline after inhalation of 1mg of terbutaline. Stable asthma during run-in
and compliant with treatment.
Exclusion Criteria: Three or more courses of oral glucocorticoids or had been hospi-
talized for asthma during the previous six months. Taking more than 2000 mcg of be-
clomethasone or 1600 mcg of budesonide daily by pressurized metered dose inhaler, 800
mcg of budesonide daily by Turbuhaler dry-powder inhaler or 800 mcg of fluticasone
daily
Interventions Budesonide 100 µg BD + Placebo
Budesonide100 µg + Formoterol 12 µg BD (9 µg delivered dose)
Budesonide 400 µg BD + Placebo
Budesonide 400 µg + Formoterol 12 µg BD (9 µg delivered dose)
Delivery was DPI
Outcomes Two primary outcome variables, the rate of severe exacerbations and the rate of mild
exacerbations, according to treatment group
SAE data (all-cause and asthma related) provided by AstraZeneca fromData on file 2008
No SAE data given in the paper publication, except asthma admissions but the sponsors
have provided data on file for the number of patients with all-cause and asthma-related
SAEs
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated randomisation sched-
ule (Ni Chroinin 2005)
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Allocation concealment? Yes The patients were randomly assigned to
treatment groups in balanced blocks of four
at each centre
Blinding?
All outcomes
Yes Double-blind
Incomplete outcome data addressed?
All outcomes
Yes 694/852 (81%) completed the study
Free of selective reporting? Yes SAE data provided from sponsors
Pauwels 1997a
Methods Study Design:A randomised, double-blind, Multicentre, parallel-group study over 12
months at 71 centres in 9 countries. (Belgium, Canada, the Netherlands, Israel, Italy,
Luxembourg, Norway, Spain and the United Kingdom). Run-in 4 weeks on 800 mcg
twice daily
Participants Study Design: A randomised, double-blind, Multicentre, parallel-group study over 12
months at 71 centres in 9 countries. (Belgium, Canada, the Netherlands, Israel, Italy,
Luxembourg, Norway, Spain and the United Kingdom) Run-in 4 weeks on 800 mcg
twice daily.
Population: 852 adults (18-70) years with persistent symptomatic asthma.
Baseline Characteristics: Mean age 42 years. FEV1 76% predicted. Concomitant in-
haled corticosteroids used by 100% of participants (mean dose 820 mcg/day).
Inclusion Criteria: 18 to 70 years old, who had asthma for at least six months and
had been treated with an inhaled glucocorticoid for at least three months. FEV1 %
predicted at least 50 %, bronchodilator reversibility by an increase of at least 15% in
FEV1 over baseline after inhalation of 1mg of terbutaline. Stable asthma during run-in
and compliant with treatment.
Exclusion Criteria: Three or more courses of oral glucocorticoids or had been hospi-
talized for asthma during the previous six months. Taking more than 2000 mcg of be-
clomethasone or 1600 mcg of budesonide daily by pressurized metered dose inhaler, 800
mcg of budesonide daily by Turbuhaler dry-powder inhaler or 800 mcg of fluticasone
daily
Interventions This report deals with patients on 800 mcg budesonide daily
Budesonide 100 µg BD + Placebo
Budesonide100 µg + Formoterol 12 µg BD (9 µg delivered dose)
Budesonide 400 µg BD + Placebo
Budesonide 400 µg + Formoterol 12 µg BD (9 µg delivered dose)
Delivery was DPI
Outcomes Two primary outcome variables, the rate of severe exacerbations and the rate of mild
exacerbations, according to treatment group
SAE data (all-cause and asthma related) provided by AstraZeneca fromData on file 2008
No SAE data given in the paper publication, except asthma admissions but the sponsors
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have provided data on file for the number of patients with all-cause and asthma-related
SAEs. There was one death (unrelated to asthma) in a participant on Budesonide 400
and Formoterol 12 twice daily
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated randomisation sched-
ule (Ni Chroinin 2005)
Allocation concealment? Yes The patients were randomly assigned to
treatment groups in balanced blocks of four
at each centre
Blinding?
All outcomes
Yes Double-blind
Incomplete outcome data addressed?
All outcomes
Yes 694/852 (81%) completed the study
Free of selective reporting? Yes SAE data provided from sponsors
Peters 2008
Methods Study Design: A randomised, double-blind, single-dummy, Multicentre, Phase III,par-
allel-group study over 52 weeks from August 2003 to February 2005 at 77 centres in the
United States
Run-in 2 weeks on budesonide 320 mcg bd (LABA discontinued).
Participants Population: 708 adults and adolescents (12 - 81) years withmoderate to severe persistent
asthma
Baseline Characteristics: Mean age 40 years. FEV1 72% predicted. Concomitant in-
haled corticosteroids used by 100% of participants (mean daily dose around 500 mcg)
Inclusion Criteria: 12 years of age and older with a documented clinical diagnosis of
moderate-to-severe asthma for at least 6months prior to screening, receivedmaintenance
asthma treatment with a stable dose of inhaled corticosteroids (ICS) for at least 4 weeks
prior to the screening visit. FEV1%predicted of at least 45%, bronchodilator reversibility
by an increase of at least 12% in FEV1 and at least 0.20 L from baseline within 15?30
minutes after administration of a fast-acting beta2-agonist or have a documented history
of this level of reversibility after administration of a fast-acting beta2-agonist while using
ICS within 1 year of screening. To require two asthma controller medications or to have
had a history of at least two asthma-related nighttime awakenings or at least three uses of
rescue medication within the week before screening. Required to be nonsmokers, with
a less than 20 pack-year smoking history.
Exclusion Criteria: had a significant disease or disorder (e.g. cardiovascular, pulmonary
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[other than asthma], hepatic, renal) that, in the opinion of the investigator, may put the
patient at risk or influence the results of the study. In addition, treated with systemic
corticosteroids within 30 days before screening or during the period between screening
and randomisation were excluded
Interventions 1. Budesonide/Formoterol 640/18 µg BD
2. Budesonide/ Formoterol 320/9 µg BD (this arm was not used in the analysis for
this review)
3. Budesonide 640 µg BD
Delivery was pMDI
Outcomes Because this study was a safety study, no single variable was considered primary. However,
spirometry (predose and 2-hour post dose FEV1 ) was conducted at each study visit to
detect any untoward decreases in lung function over the 52-week period
Web report indicates 21 patients with SAE on BDF 640/18 bd and 5 on budesonide
640 bd. No deaths in the study
Paper reports one asthma SAE in the BDF 640/18 bd group.
Notes Sponsored by AstraZeneca (SD-039-0728)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes randomised using a 3:1:1 overall randomi-
sation scheme and a computer-generated
allocation schedule
Allocation concealment? Unclear Not reported
Blinding?
All outcomes
Yes Double blind
Incomplete outcome data addressed?
All outcomes
Yes 579/708 (82%) completed the study
Free of selective reporting? Yes SAE data available from paper and web re-
port.
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Methods Study Design:A randomised, double-blind, double-dummy, active-controlled, Multi-
centre, parallel-group study over 12 weeks from March, 2002 to March, 2003 at 80
centres in 8 countries (Austria (5), Belgium (11), Czech Republic (14), France (11),
Hungary (12), Poland (17), Spain (8) and Switzerland (2))
Run-in 2 weeks on previous dose of ICS but LABA appears to have been withdrawn
from the 40% previously taking LABA?
Participants Population: 630 children (4-11) years with asthma.
Baseline Characteristics: Mean age 8 years. FEV1 92% predicted. Concomitant inhaled
corticosteroids used by 100% of participants (mean 450 mcg/day), and around 40%
had previously being taking LABA.
Inclusion Criteria: Outpatients aged 4 to 11 yr who had been diagnosed with asthma
[as defined by the American Thoracic Society] for a minimum period of 6 months, to
have a pre-bronchodilator PEF at least 50% of predicted normal and received treatment
with an ICS (any brand) for at least 3 months before entry into the study, with the
dose remaining constant (375 to1000 µg day) during the 30 days immediately prior
to enrolment, had to have a history of an average of more than 1 clinically important
exercise-induced bronchoconstriction per week during the 3 months leading up to the
study.
Exclusion Criteria: used oral, parenteral or rectal corticosteroids within 30 days of
inclusion in the study; any respiratory infection affecting asthma control within the
30 days before enrolment; any significant disease or concomitant disorder; known or
suspected hypersensitivity to the study medication or inhaled lactose. The use of inhaled
anticholinergics, beta-blockers (including eye drops), xanthines and other anti-asthma
products was not permitted during the study
Interventions 1. Budesonide/Formoterol 80/4.5 µg 2x BD
2. Budesonide 100 µg 2x BD
3. Budesonide 100 µg 2x BD + Formoterol 4.5 µg 2x BD (separate inhalers)
Equivalent budesonide in each arm (400 mcg metered dose). DPI delivery
Outcomes The primary efficacy variable was the change from baseline to treatment (average of the
12-wk treatment period) in morning peak expiratory flow (PEF)
Paper reports: ” Serious adverse events were experienced by a total of 11 patients: 3 BDF
(fracture, laryngitis, torticollis), 5 with budesonide and formoterol in separate inhalers
(appendicitis (2), vomiting, laryngitis, pneumonia) and 3 with budesonide (gastroen-
teritis (2) and fracture). There were no deaths
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Not reported
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Pohunek 2006 (Continued)
Blinding?
All outcomes
Yes Double blind
Incomplete outcome data addressed?
All outcomes
Yes 592/630 (94%) completed the study
Free of selective reporting? Yes SAE reported by treatment group and event
type in paper
Price 2002
Methods Study Design: A randomised, double-blind, Multicentre, parallel-group study in 152
general practices in the UK and Republic of Ireland and comprising two parts (4 weeks
and 24 weeks) Run-in 7 to 14 days
Participants Population: 663 adolescents and adults (12+ ) years with mild to moderate asthma (part
1), 505 continued to part 2
Baseline Characteristics: Mean age 38 years. Concomitant inhaled corticosteroids used
by 67% of participants.
Inclusion Criteria: 12 years and older with a diagnosis of asthma confirmed in the
clinical record for at least 3 months. Current treatment had to include a short acting b2
agonist alone or with an inhaled corticosteroid (< 400 mg/day beclomethasone dipropi-
onate or budesonide via pressurised metered dose inhaler, or < 200 mg/day fluticasone
or budesonide via Turbohaler) at a constant dose for > 4 weeks. Were required to have
experienced asthma symptoms (chest tightness, cough, wheeze, or shortness of breath)
on a minimum of 3 days in the week before enrolment into the study. Either reversibility
of peak expiratory flow (PEF)/forced expiratory volume in 1 second (FEV1) of > 12%
(or > 9% of predicted normal), or a diurnal variation of > 20% on at least one day during
the run in period
Exclusion Criteria: more severe or recently unstable asthma, PEF <50% predicted;
currently receiving (during 4 weeks before enrolment) nebulised therapy, oral corticos-
teroids, leukotriene antagonist, or long acting b2 agonist; a clinically relevant upper
respiratory tract infection in the 4 weeks leading up to enrolment, irreversible chronic
airways disease
Interventions 1. Budesonide 400 µg BD + eformoterol 9 µg BD
2. Budesonide 400 µg BD + placebo
Data from Part 2 used following 4 weeks stabilisation of patients on the same treatments
in part 1. DPI delivery
Outcomes In part II the primary outcome measure was time to the first mild asthma exacerbation
SAE data not reported in paper but obtained from Jaeschke 2008.
Notes Supported by grant from AstraZeneca
Risk of bias
Item Authors’ judgement Description
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Price 2002 (Continued)
Adequate sequence generation? Yes Computer generated random numbers (Ni
Chroinin 2005)
Allocation concealment? Yes Numbered coded solutions supplied by
pharmacy (Ni Chroinin 2005)
Blinding?
All outcomes
Yes Double blind
Incomplete outcome data addressed?
All outcomes
Yes 400/505 (79%) completed part 2
Free of selective reporting? Yes Data on SAEs from Jaeschke 2008
SD-039-0714
Methods A randomized, double-blind, multicentre, parallel-group study over 12 weeks from
August 2001 to September 2002 at 122 centres in the United Kingdom. (119 general
practice centres and 3 hospital centres) Run-in 2 weeks on budesonide 200 mcg twice
daily
Efficacy and safety of budesonide/formoterol Turbuhaler® (160/4.5 mg b.i.d. delivered
dose) compared to budesonide Turbuhaler® (200 mg b.i.d. metered dose) in steroid-us-
ing asthmatic adolescent patients. A double-blind, double dummy, randomised, parallel
group, phase III, multicentre study. (ATTAIN STUDY)
Participants Population: 271 steroid-using asthmatic adolescents(11 to 17) years.
Baseline Characteristics: Mean age 14 years. FEV1 75% predicted. Concomitant in-
haled corticosteroids used by 100% of participants (.
Inclusion Criteria: 12-17 years old, . FEV1 % predicted 40-90%, bronchodilator
reversibility of at least 12% in FEV1 and experiencing asthma symptoms. Receiving an
iGCS for perennial asthma, dose of iGCS within or equal to 375-1000 mg daily dose
within the licensed dose for the patients’ age,
Exclusion Criteria: not obvious
Interventions 1. Budesonide/Formoterol 160/4.5 µg BD
2. Budesonide 200 µg BD
Delivery was DPI
Outcomes am PEF as recorded daily by patients in diary.
Web report indicates no deaths and one SAE in each group (overdose on BDF and
bronchospasm on budesonide)
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
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SD-039-0714 (Continued)
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Not reported
Blinding?
All outcomes
Yes Double blind
Incomplete outcome data addressed?
All outcomes
Yes 219/271 (81%) completed the study
Free of selective reporting? Yes SAE data in web report
SD-039-0718
Methods Study Design: A randomized, double-blind, double-dummy, active-controlled study
over 12 weeks from July 2002 to October 2003 at 52 centers in the United States. Run-
in 2 weeks on 100 mcg budesonide twice daily
Participants Population: 411 children (6 -15) with mild to moderate asthma.
Baseline Characteristics: Mean age 10 years. FEV1 82% predicted. Concomitant in-
haled corticosteroids used by 100% of participants (mean 235 mcg/day).
Inclusion Criteria: 6 to 15 years of age, chronically treatedwith a low tomediumdose of
inhaled corticosteroid (ICS), FEV1 % predicted at least 50% on ICS therapy, older than
12 years, bronchodilator reversibility of at least 12% in FEV1 and at least 0.20 L from
the pre-albuterol value within 15-30 minutes after administration of a standard dose of
a fast-acting beta2-agonist (albuterol pMDI, 2 to 4 actuations [90 µg per actuation],
with or without a spacer, or after administration of up to 2.5 mg nebulized albuterol).
Younger than 12 years needed to show only reversibility of at least 12%. Alternatively,
reversibility of PEF of at least 15%, but not more than 50%, could be used by any
subject to meet the reversibility criterion.
Exclusion Criteria: not obvious
Interventions 1. Budesonide/Formoterol 40/4.5 µg 2x BD pMDI delivery
2. Budesonide 40 µg 2x BD pMDI delivery
3. Formoterol 4.5 µg 2x BD DPI delivery
Arm three not used in this review
Outcomes Primary efficacy variable: morning peak expiratory flow (PEF)
Web report lists no deaths and no patients with SAE in groups one or two
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
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SD-039-0718 (Continued)
Adequate sequence generation? Yes Randomization was stratified by age group
(children under 8 years of age versus chil-
dren 8 years and older) Subjects were ran-
domly assigned to 1 of the 3 treatment
groups
Allocation concealment? Unclear No details
Blinding?
All outcomes
Yes Double-blind. Treatments were given in
double-dummy fashion because of the dif-
ference in devices
Incomplete outcome data addressed?
All outcomes
Yes 28% dropout on BDF and 35% on budes-
onide (all randomised patients in safety
analysis and no events reported!)
Free of selective reporting? Yes SAE data on web report
SD-039-0719
Methods Study Design : A randomized, open-label, safety study over 26 weeks from July 2002
to October 2003 at 29 centers in the United States. Run-in 1 week
Participants Population: 187 children (6 -11) years with ICS-dependent asthma.
Baseline Characteristics: Mean age 9 years. FEV1 84% predicted. Concomitant inhaled
corticosteroids used by 100% of participants.
Inclusion Criteria: 6 to under 12 years of age with ICS-dependent asthma. FEV1 %
predicted at least 50%, documented historic peak expiratory flow (PEF) or FEV1 re-
versibility at least 12% from a pre-albuterol value within 15 to 30 minutes after admin-
istration of a standard dose of fast-acting B2-agonist. Subjects without a documented
history of reversibility must have demonstrated FEV1 reversibility as above at any time
before Visit 2.
Exclusion Criteria: not obvious
Interventions 1. Budesonide/Formoterol 160/4.5 µg 2x BD pMDI delivery
2. Budesonide 160 µg 2x BD TBH delivery
Outcomes Outcome: No single variable was considered to be primary. The primary objective of the
study was to assess long-term safety
Web report indicates no deaths. Two SAEs in BDF group (asthma and pneumonia) and
one on budesonide (sickle cell anaemia)
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
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SD-039-0719 (Continued)
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Not reported
Blinding?
All outcomes
No Open
Incomplete outcome data addressed?
All outcomes
Yes 87% completed the study
Free of selective reporting? Yes SAE reported fully
SD-039-0725
Methods Study Design: A randomized, double-blind, double-dummy, multicenter, active-con-
trolled, parallel group, study over 12 weeks from January 2003 to August 2004 at 128
centers in the United States. Run-in 4-5 week single-blind ( in which participants had
to be stable on budesonide/formoterol 40/4.5 mcg two puffs twice daily)
ATwelve-Week, Randomized,Double-blind,Double-Dummy, Active-Controlled Study
of SYMBICORT® pMDI Administered Once Daily in Children and Adolescents 6 to
15 Years of Age with Asthma
Participants Population: 522 children and adolescents (6 -15) years with asthma.
Baseline Characteristics: Mean age 10 years. FEV1 78% predicted. Concomitant in-
haled corticosteroids previously used by 100% of participants (mean 245 mcg/day)
Inclusion Criteria: 6 to 15 years with a documented clinical diagnosis of asthma for at
least 6 months prior to screening, and in stable condition. Should have received mainte-
nance asthma treatment with inhaled corticosteroids (ICS) for at least 4 weeks prior to
the screening visit. FEV1 % predicted of between 60%-90%, measured approximately
24 hours after the last dose of long-acting B2- agonist and 6 hours after the last dose
of short-acting B2-agonist. Subjects with an FEV1 predicted between 90-95% predicted
could be included if they had an FEV1/FVC ratio measured on screening spirometry of
less than 80%. Bronchodilator reversibility of at least 12% in FEV1 and at least 0.20 L
from baseline within 15 to 30 minutes after administration of a standard dose of fast-
acting ?2-agonist, except for subjects under 11 years of age, who were required to show
reversibility of at least 12%, but not also a change of at least 0.20 L.
Exclusion Criteria: not stated
Interventions 1. Budesonide/Formoterol 80/4.5 µg 2x QD
2. Budesonide/Formoterol 40/4.5 µg 2x BD
3. Budesonide 80 µg 2x QD
Delivery was pMDI. All groups had 160 mcg budesonide daily.
Outcomes Primary variable: evening PEF (from daily diary)
“There were no deaths at any time during the study.”
“6 subjects had an SAE during the double blind treatment period: 2 on BDF 40 bd
(abdominal pain, asthma), 3 in BDF 80 qd group (influenza, asthma -2), and one in the
budesonide group (asthma).”
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SD-039-0725 (Continued)
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomization was stratified by age (6 to
11 years of age versus 12 to 15 years of age)
at the time of screening, to ensure an ap-
proximately uniform distribution of sub-
jects across treatment groups within each
of these 2 strata
Allocation concealment? Unclear No details
Blinding?
All outcomes
Yes Double-blind. In order to maintain blind-
ing with the twice-daily dosing regimen, all
subjects randomized to receive once-daily
dosing were to receive the active treatment
in the evening and placebo treatment with
a matched device in the morning
Incomplete outcome data addressed?
All outcomes
Yes 499/521 (96%) completed the study
Free of selective reporting? Yes SAEs reported by treatment group and
cause
SD-039-0726
Methods Study Design: A randomized, double-blind, double-dummy,multicenter, parallel group,
placebo- and active-controlled study over 12 weeks from April 2003 to June 2004 at 151
centers in the United States. Run-in 4-5 week single-blind
A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-
Controlled Study of SYMBICORT® pMDI Administered Once Daily in Adults and
Adolescents with Asthma
Participants Population: 752 adolescents and adults (16 -79) years with asthma.
Baseline Characteristics: Mean age 38 years. FEV1 75% predicted. Concomitant in-
haled corticosteroids used by 100% of participants.
Inclusion Criteria: 16-years of age and older, with a documented clinical diagnosis
of asthma for at least 6 months prior to screening, and in stable condition. Received
maintenance asthma treatment with a low to medium dose of inhaled corticosteroids
(ICS) for at least 4 weeks prior to the screening visit
FEV1 % predicted of between 60%-90%, measured at least 24 hours after the last dose
of long-acting B2- agonist and 6 hours after the last dose of short-acting B2-agonist.
Exclusion Criteria: not obvious
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SD-039-0726 (Continued)
Interventions 1. Budesonide/Formoterol 160/4.5 µg 2x QD
2. Budesonide/Formoterol 80/4.5 µg 2x QD
3. Budesonide/Formoterol 80/4.5 µg 2x BD
4. Budesonide 160 µg 2x QD
Placebo arm and arm two not used in this analysis. MDI delivery
Outcomes Primary variable: evening PEF (from daily diary)
SAE data obtained from web report. Five patients suffered an SAE: Three on BDF 80
bd (breast cancer in situ, road traffic accident, musculoskeletal chest pain), one on BDF
160 daily (prostate cancer), and one on budesonide (tension headache). There were no
deaths
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Not reported
Blinding?
All outcomes
Yes Double blind
Incomplete outcome data addressed?
All outcomes
Yes 707/751 (94%) completed the study
Free of selective reporting? Yes SAE data on web report
Tal 2002
Methods Study Design: A randomized, double-blind, double-dummy, active-controlled, multi-
centre, parallel-group study over 12 weeks from November 1998 to June 1999 at 48
centres in 7 countries Hungary (6), the Czech Republic (7), the United Kingdom (11),
Spain (7), Belgium (4), Israel (4) and South Africa (4)
Run-in 2-4 weeks on budesonide 400 mcg daily (unclear if previous LABA withdrawn)
Participants Population: 286 children (4-17) years with asthma.
Baseline Characteristics: Mean age 11 years. FEV1 75% predicted. Concomitant in-
haled corticosteroids used by 100% of participants (mean 548 mcg/day), previous LABA
use not reported
Inclusion Criteria: Between 4 to 17 years of age with a diagnosis of asthma (minimum
duration, 6 months), FEV1 % predicted of 40 to 90%, bronchodilator reversibility by
an increase of at least 15% in FEV1 over baseline within 15 min of inhalation of a short-
acting b2-agonist.
Exclusion Criteria: unstable asthma (defined as the use of oral, parenteral, or rectal
corticosteroids within 30 days of study commencement), any respiratory infection af-
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Tal 2002 (Continued)
fecting disease control within the previous 4 weeks, and known hypersensitivity to study
medication or inhaled lactose
Interventions 1. Budesonide/Formoterol 80/4.5 µg 2x BD
2. Budesonide 100 µg 2x BD
Delivery was DPI
Outcomes The primary efficacy variable was the change in morning PEF from baseline to end of
treatment
“A total of 7 patients in the budesonide/formoterol group had a serious adverse event
requiring admission to hospital (asthma (5), larynx edema (1), pneumonia (1).” Deaths
are not mentioned nor are any events in the budesonide group. Further clarification
was sought from the sponsors, who have confirmed no serious adverse events in the
budesonide group
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer-generated block-randomization
list
Allocation concealment? Unclear individual treatment code envelopes pro-
vided for each subject
Blinding?
All outcomes
Yes Double-blind, double-dummy technique
Incomplete outcome data addressed?
All outcomes
Yes 268/286 (94%) completed the study
Free of selective reporting? Yes SAEs appear to be fully reported in the pa-
per.
Zetterstrom 2001
Methods Study Design: A randomized, double-blind, double-dummy, active-controlled, parallel-
group study over 12 weeks at 63 centres in 6 countries (Finland (7), Germany (12),
Ireland (6), Norway (12), Spain (11) and Sweden (15))
Run-in 2 weeks on usual inhaled corticosteroid (no mention of continuing previous
LABA)
Participants Population: 362adults (18 - 78) years with asthma not controlled with inhaled corti-
costeroids alone
Baseline Characteristics: Mean age 47 years. FEV1 74% predicted. Concomitant in-
haled corticosteroids used by 100% of participants (mean dose 960 mcg/day).
Inclusion Criteria: 18 years and older, using inhaled glucocorticosteroids at a constant
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Zetterstrom 2001 (Continued)
daily dose of at least 500 µg for at least 30 days before entry, FEV1 % predicted of 50?
90%, bronchodilator reversibility by an increase of at least 15% in FEV1 over baseline
after inhalation of terbutaline sulphate 1 mg (Bricanyl Turbuhaler) or salbutamol 0.4
mg.
Exclusion Criteria: use of oral, parenteral or rectal glucocorticosteroids within 30 days
before study entry; respiratory infection; seasonal asthma; severe cardiovascular disorder;
beta-blocker therapy; a history of heavy smoking (greater than10 pack-yrs); pregnancy
or failure to use acceptable contraceptives in women of childbearing potential
Interventions 1. Budesonide/Formoterol 160/4.5 µg 2x BD
2. Budesonide 200 µg + Formoterol 4.5 µg 2x BD
3. Budesonide 200 µg 2x BD
Delivery was DPI, equivalent to budesonide 400 mcg bd metered dose in all arms
Outcomes The primary efficacy variable was change in average morning PEF from baseline to study
end
Paper reports: “There were five serious adverse events in the single inhaler therapy group
and one in the budesonide alone group. There was one death by suicide and four hos-
pital admissions (due to pneumonia, liver cysts, ischaemic stroke and intervertebral disc
prolapse).” The sponsors have confirmed that the death was on a combined budesonide/
formoterol inhaler
Notes Sponsored by AstraZeneca
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computerized randomization occurred on
a per country basis.
Allocation concealment? Yes individual treatment codes were kept in
sealed envelopes until data analysis
Blinding?
All outcomes
Yes Double-blind, patients successively used
three numbered inhalers (identical in ap-
pearance to the corresponding placebo)
each morning and evening
Incomplete outcome data addressed?
All outcomes
Yes 309/362 (85%) completed the study
Free of selective reporting? Yes SAE by treatment group in paper.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ankerst 2003 Short term crossover study
AstraZeneca 2005 Comparison with Budesonide and Theophylline
AstraZeneca 2005a Ongoing study
AstraZeneca 2005b Comparison of Single Inhaler Therapy with Current Best Practice
AstraZeneca 2005c Comparison of Single Inhaler Therapy with Current Best Practice
AstraZeneca 2005d Comparison of Single Inhaler Therapy with Current Best Practice
AstraZeneca 2006 Comparison of Single Inhaler Therapy with ICS and terbutaline
AstraZeneca 2006a Comparison of Single Inhaler Therapy with Current Best Practice
AstraZeneca 2006b Comparison of Single Inhaler Therapy with Current Best Practice
Balanag 2006 Comparison to salbutamol in acute asthma
Bateman 2003 BDF compared to higher dose Fluticasone
Bateman 2006 Acute asthma
Bouros 1999 Formoterol and beclometasone compared to higher dose beclometasone
Buhl 2004 Adjustable versus fixed dose BDF
Burgess 1998 Short term cross-over study
Canonica 2004 Adjustable versus fixed dose BDF
Ceylan 2004 Formoterol in comparison with montelukast in addition to low dose ICS
Dhillon 2006 Review of beclometasone/formoterol treatment
FitzGerald 1999 No randomisation to ICS
FitzGerald 2003 Adjustable versus fixed dose BDF
Haahtela 2006 Formoterol used as needed (with or without budesonide)
Ind 2004 Adjustable versus fixed dose BDF
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Kozlik-Feldmann 1996 No randomisation to ICS
Lalloo 2003 BDF compared to higher dose ICS
Leuppi 2003 Adjustable versus fixed dose BDF
Lotvall Short term comparison of bronchodilation following FPS and BDF
Lundborg 2006 Cost effectiveness of Single inhaler therapy
Mitchell 2003 Comparison with higher dose ICS
Molimard 2001 Not randomised to ICS
Novartis 2005 No randomisation to ICS
O’Byrne 2005 BDF as single inhaler therapy or fixed dose compared to higher dose budesonide
Overbeek 2005 Duration of less than 12 weeks on each dose of budesonide
Papi 2007 Delivery device comparison for beclometasone/formoterol combination inhalers
Pauwels 2003 Comparison of formoterol with salbutamol as relief medication
Pleskow 2003 Not randomised to ICS
Pohl 2006 Adjustable Maintenance Dosing study
Rabe 2006 BDF single inhaler therapy compared to higher dose budesonide
Rosenhall 2002 Combined BDF inhaler compared to both medications given together in separate inhalers
Rosenhall 2003 Combined BDF inhaler compared to both medications given together in separate inhalers
Rosenhall 2003a Combined BDF inhaler compared to both medications given together in separate inhalers
Scicchitano 2004 BDF single inhaler therapy compared to higher dose budesonide
Stelmach 2007 4 week study
van der Molen 1997 No randomisation to inhaled corticosteroids
Villa, 2002 Formoterol as needed compared to terbutaline as needed
Von Berg 2003 No randomisation to ICS
Worth 2005 Single inhaler therapy compared to current best practice
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Zetterstrom 2001a Single inhaler therapy
Zetterström 2000 Single inhaler therapy
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D A T A A N D A N A L Y S E S
Comparison 1. Formoterol and ICS versus same dose ICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause Mortality 23 10816 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.83 [0.78, 43.77]
1.1 Adults and Adolescents 16 8028 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.83 [0.78, 43.77]
1.2 Children and Adolescents 7 2788 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
2 All-cause non-fatal Serious
Adverse Events
23 10816 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.06 [0.81, 1.39]
2.1 Adults and Adolescents 16 8028 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.74, 1.33]
2.2 Children and Adolescents 7 2788 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.62 [0.80, 3.28]
3 Asthma Mortality 23 Peto Odds Ratio (Peto, Fixed, 95% CI) Totals not selected
3.1 Adults and Adolescents 16 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
3.2 Children and Adolescents 7 Peto Odds Ratio (Peto, Fixed, 95% CI) Not estimable
4 Asthma-related non-fatal Serious
Adverse Events
23 10816 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.68 [0.39, 1.18]
4.1 Adults and Adolescents 16 8028 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.53 [0.28, 1.00]
4.2 Children and Adolescents 7 2788 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.49 [0.48, 4.61]
5 All-cause Mortality (risk
difference)
23 10816 Risk Difference (M-H, Fixed, 95% CI) Not estimable
5.1 Adults and Adolescents 16 8028 Risk Difference (M-H, Fixed, 95% CI) Not estimable
5.2 Children and Adolescents 7 2788 Risk Difference (M-H, Fixed, 95% CI) Not estimable
6 All-cause non-fatal Serious
Adverse Events (risk difference)
23 10816 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.00, 0.01]
6.1 Adults and Adolescents 16 8028 Risk Difference (M-H, Fixed, 95% CI) Not estimable
6.2 Children and Adolescents 7 2788 Risk Difference (M-H, Fixed, 95% CI) 0.01 [-0.00, 0.01]
7 Asthma-related non-fatal Serious
Adverse Events (risk difference)
23 10816 Risk Difference (M-H, Fixed, 95% CI) -0.00 [-0.01, 0.00]
7.1 Adults and Adolescents 16 8028 Risk Difference (M-H, Fixed, 95% CI) Not estimable
7.2 Children and Adolescents 7 2788 Risk Difference (M-H, Fixed, 95% CI) 0.00 [-0.00, 0.01]
8 All-cause Mortality
(Mantel-Haenszel fixed)
23 10816 Odds Ratio (M-H, Fixed, 95% CI) 2.15 [0.43, 10.67]
8.1 Adults and Adolescents 16 8028 Odds Ratio (M-H, Fixed, 95% CI) 2.15 [0.43, 10.67]
8.2 Children and Adolescents 7 2788 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
9 All-cause non-fatal
Serious Adverse Events
(Mantel-Haenszel fixed)
23 10816 Odds Ratio (M-H, Fixed, 95% CI) 1.06 [0.81, 1.38]
9.1 Adults and Adolescents 16 8028 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.74, 1.31]
9.2 Children and Adolescents 7 2788 Odds Ratio (M-H, Fixed, 95% CI) 1.62 [0.77, 3.38]
10 All-cause non-fatal Serious
Adverse Events (sensitivity
analysis without unblinded
study)
22 10630 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.06 [0.81, 1.40]
10.1 Adults and Adolescents 16 8028 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.99 [0.74, 1.33]
10.2 Children and Adolescents 6 2602 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.69 [0.81, 3.54]
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Analysis 1.1. Comparison 1 Formoterol and ICS versus same dose ICS, Outcome 1 All-cause Mortality.
Review: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
Comparison: 1 Formoterol and ICS versus same dose ICS
Outcome: 1 All-cause Mortality
Study or subgroup Formoterol and ICS Same Dose ICS
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults and Adolescents
Buhl 2003 1/352 0/171 4.42 [ 0.07, 288.27 ]
Chuchalin 2002 0/111 0/114 0.0 [ 0.0, 0.0 ]
Corren 2007 0/123 0/121 0.0 [ 0.0, 0.0 ]
D5896C00001 0/312 0/153 0.0 [ 0.0, 0.0 ]
Jenkins 2006 0/341 0/115 0.0 [ 0.0, 0.0 ]
Kuna 2006 0/409 0/207 0.0 [ 0.0, 0.0 ]
Morice 2007 0/462 0/217 0.0 [ 0.0, 0.0 ]
Noonan 2006 0/239 0/109 0.0 [ 0.0, 0.0 ]
O’Byrne 2001 1/554 0/550 7.34 [ 0.15, 369.72 ]
O’Byrne 2001a 0/315 0/312 0.0 [ 0.0, 0.0 ]
Pauwels 1997 0/210 0/213 0.0 [ 0.0, 0.0 ]
Pauwels 1997a 1/215 0/214 7.35 [ 0.15, 370.66 ]
Peters 2008 0/443 0/133 0.0 [ 0.0, 0.0 ]
Price 2002 0/250 0/255 0.0 [ 0.0, 0.0 ]
SD-039-0726 0/301 0/145 0.0 [ 0.0, 0.0 ]
Zetterstrom 2001 1/238 0/124 4.58 [ 0.07, 284.60 ]
Subtotal (95% CI) 4875 3153 5.83 [ 0.78, 43.77 ]
Total events: 4 (Formoterol and ICS), 0 (Same Dose ICS)
Heterogeneity: Chi2 = 0.06, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
2 Children and Adolescents
Morice 2008 0/415 0/207 0.0 [ 0.0, 0.0 ]
Pohunek 2006 0/417 0/213 0.0 [ 0.0, 0.0 ]
SD-039-0714 0/136 0/134 0.0 [ 0.0, 0.0 ]
SD-039-0718 0/128 0/145 0.0 [ 0.0, 0.0 ]
SD-039-0719 0/123 0/63 0.0 [ 0.0, 0.0 ]
0.001 0.01 0.1 1 10 100 1000
Favours Formoterol % ICS Favours same dose ICS
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(. . . Continued)
Study or subgroup Formoterol and ICS Same Dose ICS
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
SD-039-0725 0/352 0/169 0.0 [ 0.0, 0.0 ]
Tal 2002 0/148 0/138 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1719 1069 0.0 [ 0.0, 0.0 ]
Total events: 0 (Formoterol and ICS), 0 (Same Dose ICS)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 6594 4222 5.83 [ 0.78, 43.77 ]
Total events: 4 (Formoterol and ICS), 0 (Same Dose ICS)
Heterogeneity: Chi2 = 0.06, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours Formoterol % ICS Favours same dose ICS
Analysis 1.2. Comparison 1 Formoterol and ICS versus same dose ICS, Outcome 2 All-cause non-fatal
Serious Adverse Events.
Review: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
Comparison: 1 Formoterol and ICS versus same dose ICS
Outcome: 2 All-cause non-fatal Serious Adverse Events
Study or subgroup Formoterol and ICS Same Dose ICS
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults and Adolescents
Buhl 2003 2/352 2/171 0.45 [ 0.06, 3.68 ]
Chuchalin 2002 0/111 2/114 0.14 [ 0.01, 2.22 ]
Corren 2007 2/123 0/121 7.33 [ 0.46, 117.87 ]
D5896C00001 3/312 0/153 4.47 [ 0.40, 49.92 ]
Jenkins 2006 7/341 3/115 0.77 [ 0.18, 3.26 ]
Kuna 2006 3/409 4/207 0.34 [ 0.07, 1.67 ]
Morice 2007 2/462 2/217 0.43 [ 0.05, 3.57 ]
0.001 0.01 0.1 1 10 100 1000
Favours Formoterol % ICS Favours same dose ICS
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(. . . Continued)
Study or subgroup Formoterol and ICS Same Dose ICS
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Noonan 2006 7/239 0/109 4.40 [ 0.88, 22.04 ]
O’Byrne 2001 20/554 23/550 0.86 [ 0.47, 1.58 ]
O’Byrne 2001a 15/315 19/312 0.77 [ 0.39, 1.54 ]
Pauwels 1997 10/210 9/213 1.13 [ 0.45, 2.84 ]
Pauwels 1997a 15/215 12/214 1.26 [ 0.58, 2.75 ]
Peters 2008 21/443 5/133 1.26 [ 0.49, 3.19 ]
Price 2002 2/250 3/255 0.68 [ 0.12, 3.96 ]
SD-039-0726 4/301 1/145 1.78 [ 0.27, 11.65 ]
Zetterstrom 2001 3/238 1/124 1.51 [ 0.19, 12.04 ]
Subtotal (95% CI) 4875 3153 0.99 [ 0.74, 1.33 ]
Total events: 116 (Formoterol and ICS), 86 (Same Dose ICS)
Heterogeneity: Chi2 = 13.79, df = 15 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
2 Children and Adolescents
Morice 2008 2/415 3/207 0.30 [ 0.05, 1.93 ]
Pohunek 2006 8/417 3/213 1.35 [ 0.38, 4.74 ]
SD-039-0714 1/136 1/134 0.99 [ 0.06, 15.83 ]
SD-039-0718 0/128 0/145 0.0 [ 0.0, 0.0 ]
SD-039-0719 2/123 1/63 1.02 [ 0.09, 11.34 ]
SD-039-0725 5/352 1/169 2.07 [ 0.37, 11.52 ]
Tal 2002 7/148 0/138 7.20 [ 1.61, 32.21 ]
Subtotal (95% CI) 1719 1069 1.62 [ 0.80, 3.28 ]
Total events: 25 (Formoterol and ICS), 9 (Same Dose ICS)
Heterogeneity: Chi2 = 7.39, df = 5 (P = 0.19); I2 =32%
Test for overall effect: Z = 1.34 (P = 0.18)
Total (95% CI) 6594 4222 1.06 [ 0.81, 1.39 ]
Total events: 141 (Formoterol and ICS), 95 (Same Dose ICS)
Heterogeneity: Chi2 = 22.78, df = 21 (P = 0.36); I2 =8%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 1.60, df = 1 (P = 0.21), I2 =37%
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.3. Comparison 1 Formoterol and ICS versus same dose ICS, Outcome 3 Asthma Mortality.
Review: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
Comparison: 1 Formoterol and ICS versus same dose ICS
Outcome: 3 Asthma Mortality
Study or subgroup Formoterol and ICS Same Dose ICS
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults and Adolescents
Buhl 2003 0/352 0/171 0.0 [ 0.0, 0.0 ]
Chuchalin 2002 0/111 0/114 0.0 [ 0.0, 0.0 ]
Corren 2007 0/123 0/121 0.0 [ 0.0, 0.0 ]
D5896C00001 0/312 0/153 0.0 [ 0.0, 0.0 ]
Jenkins 2006 0/341 0/115 0.0 [ 0.0, 0.0 ]
Kuna 2006 0/409 0/207 0.0 [ 0.0, 0.0 ]
Morice 2007 0/462 0/217 0.0 [ 0.0, 0.0 ]
Noonan 2006 0/239 0/109 0.0 [ 0.0, 0.0 ]
O’Byrne 2001 1/554 0/550 7.34 [ 0.15, 369.72 ]
O’Byrne 2001a 0/315 0/312 0.0 [ 0.0, 0.0 ]
Pauwels 1997 0/210 0/213 0.0 [ 0.0, 0.0 ]
Pauwels 1997a 0/215 0/214 0.0 [ 0.0, 0.0 ]
Peters 2008 0/443 0/133 0.0 [ 0.0, 0.0 ]
Price 2002 0/250 0/255 0.0 [ 0.0, 0.0 ]
SD-039-0726 0/301 0/145 0.0 [ 0.0, 0.0 ]
Zetterstrom 2001 0/238 0/124 0.0 [ 0.0, 0.0 ]
2 Children and Adolescents
Morice 2008 0/415 0/207 0.0 [ 0.0, 0.0 ]
Pohunek 2006 0/417 0/213 0.0 [ 0.0, 0.0 ]
SD-039-0714 0/136 0/134 0.0 [ 0.0, 0.0 ]
SD-039-0718 0/128 0/145 0.0 [ 0.0, 0.0 ]
SD-039-0719 0/123 0/63 0.0 [ 0.0, 0.0 ]
SD-039-0725 0/352 0/169 0.0 [ 0.0, 0.0 ]
Tal 2002 0/148 0/138 0.0 [ 0.0, 0.0 ]
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.4. Comparison 1 Formoterol and ICS versus same dose ICS, Outcome 4 Asthma-related non-
fatal Serious Adverse Events.
Review: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
Comparison: 1 Formoterol and ICS versus same dose ICS
Outcome: 4 Asthma-related non-fatal Serious Adverse Events
Study or subgroup Formoterol and ICS Same Dose ICS
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults and Adolescents
Buhl 2003 1/352 0/171 4.42 [ 0.07, 288.27 ]
Chuchalin 2002 0/111 1/114 0.14 [ 0.00, 7.00 ]
Corren 2007 0/123 0/121 0.0 [ 0.0, 0.0 ]
D5896C00001 0/312 0/153 0.0 [ 0.0, 0.0 ]
Jenkins 2006 0/341 0/115 0.0 [ 0.0, 0.0 ]
Kuna 2006 1/409 2/207 0.23 [ 0.02, 2.49 ]
Morice 2007 0/462 1/217 0.04 [ 0.00, 2.93 ]
Noonan 2006 2/239 0/109 4.31 [ 0.22, 85.86 ]
O’Byrne 2001 3/554 4/550 0.74 [ 0.17, 3.29 ]
O’Byrne 2001a 4/315 7/312 0.57 [ 0.17, 1.87 ]
Pauwels 1997 1/210 3/213 0.37 [ 0.05, 2.65 ]
Pauwels 1997a 2/215 5/214 0.42 [ 0.09, 1.86 ]
Peters 2008 1/443 0/133 3.67 [ 0.04, 384.21 ]
Price 2002 0/250 1/255 0.14 [ 0.00, 6.96 ]
SD-039-0726 0/301 0/145 0.0 [ 0.0, 0.0 ]
Zetterstrom 2001 0/238 0/124 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 4875 3153 0.53 [ 0.28, 1.00 ]
Total events: 15 (Formoterol and ICS), 24 (Same Dose ICS)
Heterogeneity: Chi2 = 6.72, df = 10 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
2 Children and Adolescents
Morice 2008 0/415 2/207 0.05 [ 0.00, 0.94 ]
Pohunek 2006 0/417 0/213 0.0 [ 0.0, 0.0 ]
SD-039-0714 0/136 1/134 0.13 [ 0.00, 6.72 ]
SD-039-0718 0/128 0/145 0.0 [ 0.0, 0.0 ]
0.001 0.01 0.1 1 10 100 1000
Favours Formoterol % ICS Favours same dose ICS
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Study or subgroup Formoterol and ICS Same Dose ICS
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
SD-039-0719 1/123 0/63 4.54 [ 0.07, 285.29 ]
SD-039-0725 3/352 1/169 1.41 [ 0.17, 11.48 ]
Tal 2002 5/148 0/138 7.10 [ 1.21, 41.53 ]
Subtotal (95% CI) 1719 1069 1.49 [ 0.48, 4.61 ]
Total events: 9 (Formoterol and ICS), 4 (Same Dose ICS)
Heterogeneity: Chi2 = 9.89, df = 4 (P = 0.04); I2 =60%
Test for overall effect: Z = 0.70 (P = 0.49)
Total (95% CI) 6594 4222 0.68 [ 0.39, 1.18 ]
Total events: 24 (Formoterol and ICS), 28 (Same Dose ICS)
Heterogeneity: Chi2 = 19.08, df = 15 (P = 0.21); I2 =21%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Chi2 = 2.48, df = 1 (P = 0.12), I2 =60%
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.5. Comparison 1 Formoterol and ICS versus same dose ICS, Outcome 5 All-cause Mortality (risk
difference).
Review: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
Comparison: 1 Formoterol and ICS versus same dose ICS
Outcome: 5 All-cause Mortality (risk difference)
Study or subgroup Formoterol and ICS Same Dose ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults and Adolescents
Buhl 2003 1/352 0/171 4.6 % 0.00 [ -0.01, 0.01 ]
Chuchalin 2002 0/111 0/114 2.3 % 0.0 [ -0.02, 0.02 ]
Corren 2007 0/123 0/121 2.5 % 0.0 [ -0.02, 0.02 ]
D5896C00001 0/312 0/153 4.1 % 0.0 [ -0.01, 0.01 ]
Jenkins 2006 0/341 0/115 3.5 % 0.0 [ -0.01, 0.01 ]
Kuna 2006 0/409 0/207 5.5 % 0.0 [ -0.01, 0.01 ]
Morice 2007 0/462 0/217 6.0 % 0.0 [ -0.01, 0.01 ]
Noonan 2006 0/239 0/109 3.0 % 0.0 [ -0.01, 0.01 ]
O’Byrne 2001 1/554 0/550 11.1 % 0.00 [ 0.00, 0.01 ]
O’Byrne 2001a 0/315 0/312 6.3 % 0.0 [ -0.01, 0.01 ]
Pauwels 1997 0/210 0/213 4.3 % 0.0 [ -0.01, 0.01 ]
Pauwels 1997a 1/215 0/214 4.3 % 0.00 [ -0.01, 0.02 ]
Peters 2008 0/443 0/133 4.1 % 0.0 [ -0.01, 0.01 ]
Price 2002 0/250 0/255 5.1 % 0.0 [ -0.01, 0.01 ]
SD-039-0726 0/301 0/145 4.0 % 0.0 [ -0.01, 0.01 ]
Zetterstrom 2001 1/238 0/124 3.3 % 0.00 [ -0.01, 0.02 ]
Subtotal (95% CI) 4875 3153 74.1 % 0.00 [ 0.00, 0.00 ]
Total events: 4 (Formoterol and ICS), 0 (Same Dose ICS)
Heterogeneity: Chi2 = 1.21, df = 15 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Children and Adolescents
Morice 2008 0/415 0/207 5.6 % 0.0 [ -0.01, 0.01 ]
Pohunek 2006 0/417 0/213 5.7 % 0.0 [ -0.01, 0.01 ]
SD-039-0714 0/136 0/134 2.7 % 0.0 [ -0.01, 0.01 ]
SD-039-0718 0/128 0/145 2.7 % 0.0 [ -0.01, 0.01 ]
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Study or subgroup Formoterol and ICS Same Dose ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SD-039-0719 0/123 0/63 1.7 % 0.0 [ -0.02, 0.02 ]
SD-039-0725 0/352 0/169 4.6 % 0.0 [ -0.01, 0.01 ]
Tal 2002 0/148 0/138 2.9 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 1719 1069 25.9 % 0.0 [ 0.00, 0.00 ]
Total events: 0 (Formoterol and ICS), 0 (Same Dose ICS)
Heterogeneity: Chi2 = 0.0, df = 6 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
Total (95% CI) 6594 4222 100.0 % 0.00 [ 0.00, 0.00 ]
Total events: 4 (Formoterol and ICS), 0 (Same Dose ICS)
Heterogeneity: Chi2 = 1.30, df = 22 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 1.6. Comparison 1 Formoterol and ICS versus same dose ICS, Outcome 6 All-cause non-fatal
Serious Adverse Events (risk difference).
Review: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
Comparison: 1 Formoterol and ICS versus same dose ICS
Outcome: 6 All-cause non-fatal Serious Adverse Events (risk difference)
Study or subgroup Formoterol and ICS Same Dose ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults and Adolescents
Buhl 2003 2/352 2/171 4.6 % -0.01 [ -0.02, 0.01 ]
Chuchalin 2002 0/111 2/114 2.3 % -0.02 [ -0.05, 0.01 ]
Corren 2007 2/123 0/121 2.5 % 0.02 [ -0.01, 0.04 ]
D5896C00001 3/312 0/153 4.1 % 0.01 [ -0.01, 0.02 ]
Jenkins 2006 7/341 3/115 3.5 % -0.01 [ -0.04, 0.03 ]
Kuna 2006 3/409 4/207 5.5 % -0.01 [ -0.03, 0.01 ]
Morice 2007 2/462 2/217 6.0 % 0.00 [ -0.02, 0.01 ]
Noonan 2006 7/239 0/109 3.0 % 0.03 [ 0.00, 0.05 ]
O’Byrne 2001 20/554 23/550 11.1 % -0.01 [ -0.03, 0.02 ]
O’Byrne 2001a 15/315 19/312 6.3 % -0.01 [ -0.05, 0.02 ]
Pauwels 1997 10/210 9/213 4.3 % 0.01 [ -0.03, 0.04 ]
Pauwels 1997a 15/215 12/214 4.3 % 0.01 [ -0.03, 0.06 ]
Peters 2008 21/443 5/133 4.1 % 0.01 [ -0.03, 0.05 ]
Price 2002 2/250 3/255 5.1 % 0.00 [ -0.02, 0.01 ]
SD-039-0726 4/301 1/145 4.0 % 0.01 [ -0.01, 0.03 ]
Zetterstrom 2001 3/238 1/124 3.3 % 0.00 [ -0.02, 0.03 ]
Subtotal (95% CI) 4875 3153 74.1 % 0.00 [ -0.01, 0.01 ]
Total events: 116 (Formoterol and ICS), 86 (Same Dose ICS)
Heterogeneity: Chi2 = 14.15, df = 15 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
2 Children and Adolescents
Morice 2008 2/415 3/207 5.6 % -0.01 [ -0.03, 0.01 ]
Pohunek 2006 8/417 3/213 5.7 % 0.01 [ -0.02, 0.03 ]
SD-039-0714 1/136 1/134 2.7 % 0.00 [ -0.02, 0.02 ]
SD-039-0718 0/128 0/145 2.7 % 0.0 [ -0.01, 0.01 ]
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Study or subgroup Formoterol and ICS Same Dose ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SD-039-0719 2/123 1/63 1.7 % 0.00 [ -0.04, 0.04 ]
SD-039-0725 5/352 1/169 4.6 % 0.01 [ -0.01, 0.03 ]
Tal 2002 7/148 0/138 2.9 % 0.05 [ 0.01, 0.08 ]
Subtotal (95% CI) 1719 1069 25.9 % 0.01 [ 0.00, 0.01 ]
Total events: 25 (Formoterol and ICS), 9 (Same Dose ICS)
Heterogeneity: Chi2 = 9.05, df = 6 (P = 0.17); I2 =34%
Test for overall effect: Z = 1.32 (P = 0.19)
Total (95% CI) 6594 4222 100.0 % 0.00 [ 0.00, 0.01 ]
Total events: 141 (Formoterol and ICS), 95 (Same Dose ICS)
Heterogeneity: Chi2 = 22.49, df = 22 (P = 0.43); I2 =2%
Test for overall effect: Z = 0.45 (P = 0.66)
-0.02 -0.01 0 0.01 0.02
Favours Formoterol % ICS Favours same dose ICS
73Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 Formoterol and ICS versus same dose ICS, Outcome 7 Asthma-related non-
fatal Serious Adverse Events (risk difference).
Review: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
Comparison: 1 Formoterol and ICS versus same dose ICS
Outcome: 7 Asthma-related non-fatal Serious Adverse Events (risk difference)
Study or subgroup Formoterol and ICS Same Dose ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults and Adolescents
Buhl 2003 1/352 0/171 4.6 % 0.00 [ -0.01, 0.01 ]
Chuchalin 2002 0/111 1/114 2.3 % -0.01 [ -0.03, 0.02 ]
Corren 2007 0/123 0/121 2.5 % 0.0 [ -0.02, 0.02 ]
D5896C00001 0/312 0/153 4.1 % 0.0 [ -0.01, 0.01 ]
Jenkins 2006 0/341 0/115 3.5 % 0.0 [ -0.01, 0.01 ]
Kuna 2006 1/409 2/207 5.5 % -0.01 [ -0.02, 0.01 ]
Morice 2007 0/462 1/217 6.0 % 0.00 [ -0.02, 0.01 ]
Noonan 2006 2/239 0/109 3.0 % 0.01 [ -0.01, 0.03 ]
O’Byrne 2001 3/554 4/550 11.1 % 0.00 [ -0.01, 0.01 ]
O’Byrne 2001a 4/315 7/312 6.3 % -0.01 [ -0.03, 0.01 ]
Pauwels 1997 1/210 3/213 4.3 % -0.01 [ -0.03, 0.01 ]
Pauwels 1997a 2/215 5/214 4.3 % -0.01 [ -0.04, 0.01 ]
Peters 2008 1/443 0/133 4.1 % 0.00 [ -0.01, 0.01 ]
Price 2002 0/250 1/255 5.1 % 0.00 [ -0.01, 0.01 ]
SD-039-0726 0/301 0/145 4.0 % 0.0 [ -0.01, 0.01 ]
Zetterstrom 2001 0/238 0/124 3.3 % 0.0 [ -0.01, 0.01 ]
Subtotal (95% CI) 4875 3153 74.1 % 0.00 [ -0.01, 0.00 ]
Total events: 15 (Formoterol and ICS), 24 (Same Dose ICS)
Heterogeneity: Chi2 = 7.47, df = 15 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.70 (P = 0.089)
2 Children and Adolescents
Morice 2008 0/415 2/207 5.6 % -0.01 [ -0.02, 0.01 ]
Pohunek 2006 0/417 0/213 5.7 % 0.0 [ -0.01, 0.01 ]
SD-039-0714 0/136 1/134 2.7 % -0.01 [ -0.03, 0.01 ]
SD-039-0718 0/128 0/145 2.7 % 0.0 [ -0.01, 0.01 ]
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Study or subgroup Formoterol and ICS Same Dose ICS
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SD-039-0719 1/123 0/63 1.7 % 0.01 [ -0.02, 0.04 ]
SD-039-0725 3/352 1/169 4.6 % 0.00 [ -0.01, 0.02 ]
Tal 2002 5/148 0/138 2.9 % 0.03 [ 0.00, 0.07 ]
Subtotal (95% CI) 1719 1069 25.9 % 0.00 [ 0.00, 0.01 ]
Total events: 9 (Formoterol and ICS), 4 (Same Dose ICS)
Heterogeneity: Chi2 = 7.40, df = 6 (P = 0.29); I2 =19%
Test for overall effect: Z = 0.56 (P = 0.58)
Total (95% CI) 6594 4222 100.0 % 0.00 [ -0.01, 0.00 ]
Total events: 24 (Formoterol and ICS), 28 (Same Dose ICS)
Heterogeneity: Chi2 = 13.67, df = 22 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
-0.05 -0.03 0 0.03 0.05
Favours Formoterol % ICS Favours same dose ICS
Analysis 1.8. Comparison 1 Formoterol and ICS versus same dose ICS, Outcome 8 All-cause Mortality
(Mantel-Haenszel fixed).
Review: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
Comparison: 1 Formoterol and ICS versus same dose ICS
Outcome: 8 All-cause Mortality (Mantel-Haenszel fixed)
Study or subgroup Formoterol and ICS Same Dose ICS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults and Adolescents
Buhl 2003 1/352 0/171 1.46 [ 0.06, 36.12 ]
Chuchalin 2002 0/111 0/114 0.0 [ 0.0, 0.0 ]
Corren 2007 0/123 0/121 0.0 [ 0.0, 0.0 ]
D5896C00001 0/312 0/153 0.0 [ 0.0, 0.0 ]
Jenkins 2006 0/341 0/115 0.0 [ 0.0, 0.0 ]
Kuna 2006 0/409 0/207 0.0 [ 0.0, 0.0 ]
Morice 2007 0/462 0/217 0.0 [ 0.0, 0.0 ]
0.001 0.01 0.1 1 10 100 1000
Favours Formoterol % ICS Favours same dose ICS
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(. . . Continued)
Study or subgroup Formoterol and ICS Same Dose ICS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Noonan 2006 0/239 0/109 0.0 [ 0.0, 0.0 ]
O’Byrne 2001 1/554 0/550 2.98 [ 0.12, 73.40 ]
O’Byrne 2001a 0/315 0/312 0.0 [ 0.0, 0.0 ]
Pauwels 1997 0/210 0/213 0.0 [ 0.0, 0.0 ]
Pauwels 1997a 1/215 0/214 3.00 [ 0.12, 74.06 ]
Peters 2008 0/443 0/133 0.0 [ 0.0, 0.0 ]
Price 2002 0/250 0/255 0.0 [ 0.0, 0.0 ]
SD-039-0726 0/301 0/145 0.0 [ 0.0, 0.0 ]
Zetterstrom 2001 1/238 0/124 1.57 [ 0.06, 38.89 ]
Subtotal (95% CI) 4875 3153 2.15 [ 0.43, 10.67 ]
Total events: 4 (Formoterol and ICS), 0 (Same Dose ICS)
Heterogeneity: Chi2 = 0.17, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
2 Children and Adolescents
Morice 2008 0/415 0/207 0.0 [ 0.0, 0.0 ]
Pohunek 2006 0/417 0/213 0.0 [ 0.0, 0.0 ]
SD-039-0714 0/136 0/134 0.0 [ 0.0, 0.0 ]
SD-039-0718 0/128 0/145 0.0 [ 0.0, 0.0 ]
SD-039-0719 0/123 0/63 0.0 [ 0.0, 0.0 ]
SD-039-0725 0/352 0/169 0.0 [ 0.0, 0.0 ]
Tal 2002 0/148 0/138 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1719 1069 0.0 [ 0.0, 0.0 ]
Total events: 0 (Formoterol and ICS), 0 (Same Dose ICS)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 6594 4222 2.15 [ 0.43, 10.67 ]
Total events: 4 (Formoterol and ICS), 0 (Same Dose ICS)
Heterogeneity: Chi2 = 0.17, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
0.001 0.01 0.1 1 10 100 1000
Favours Formoterol % ICS Favours same dose ICS
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Analysis 1.9. Comparison 1 Formoterol and ICS versus same dose ICS, Outcome 9 All-cause non-fatal
Serious Adverse Events (Mantel-Haenszel fixed).
Review: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
Comparison: 1 Formoterol and ICS versus same dose ICS
Outcome: 9 All-cause non-fatal Serious Adverse Events (Mantel-Haenszel fixed)
Study or subgroup Formoterol and ICS Same Dose ICS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults and Adolescents
Buhl 2003 2/352 2/171 0.48 [ 0.07, 3.46 ]
Chuchalin 2002 0/111 2/114 0.20 [ 0.01, 4.25 ]
Corren 2007 2/123 0/121 5.00 [ 0.24, 105.24 ]
D5896C00001 3/312 0/153 3.47 [ 0.18, 67.64 ]
Jenkins 2006 7/341 3/115 0.78 [ 0.20, 3.08 ]
Kuna 2006 3/409 4/207 0.38 [ 0.08, 1.69 ]
Morice 2007 2/462 2/217 0.47 [ 0.07, 3.34 ]
Noonan 2006 7/239 0/109 7.06 [ 0.40, 124.81 ]
O’Byrne 2001 20/554 23/550 0.86 [ 0.47, 1.58 ]
O’Byrne 2001a 15/315 19/312 0.77 [ 0.38, 1.55 ]
Pauwels 1997 10/210 9/213 1.13 [ 0.45, 2.85 ]
Pauwels 1997a 15/215 12/214 1.26 [ 0.58, 2.76 ]
Peters 2008 21/443 5/133 1.27 [ 0.47, 3.45 ]
Price 2002 2/250 3/255 0.68 [ 0.11, 4.09 ]
SD-039-0726 4/301 1/145 1.94 [ 0.21, 17.51 ]
Zetterstrom 2001 3/238 1/124 1.57 [ 0.16, 15.25 ]
Subtotal (95% CI) 4875 3153 0.98 [ 0.74, 1.31 ]
Total events: 116 (Formoterol and ICS), 86 (Same Dose ICS)
Heterogeneity: Chi2 = 9.46, df = 15 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
2 Children and Adolescents
Morice 2008 2/415 3/207 0.33 [ 0.05, 1.99 ]
Pohunek 2006 8/417 3/213 1.37 [ 0.36, 5.21 ]
SD-039-0714 1/136 1/134 0.99 [ 0.06, 15.91 ]
SD-039-0718 0/128 0/145 0.0 [ 0.0, 0.0 ]
SD-039-0719 2/123 1/63 1.02 [ 0.09, 11.52 ]
0.001 0.01 0.1 1 10 100 1000
Favours Formoterol % ICS Favours same dose ICS
(Continued . . . )
77Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Formoterol and ICS Same Dose ICS Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
SD-039-0725 5/352 1/169 2.42 [ 0.28, 20.88 ]
Tal 2002 7/148 0/138 14.68 [ 0.83, 259.54 ]
Subtotal (95% CI) 1719 1069 1.62 [ 0.77, 3.38 ]
Total events: 25 (Formoterol and ICS), 9 (Same Dose ICS)
Heterogeneity: Chi2 = 5.73, df = 5 (P = 0.33); I2 =13%
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 6594 4222 1.06 [ 0.81, 1.38 ]
Total events: 141 (Formoterol and ICS), 95 (Same Dose ICS)
Heterogeneity: Chi2 = 15.48, df = 21 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
0.001 0.01 0.1 1 10 100 1000
Favours Formoterol % ICS Favours same dose ICS
Analysis 1.10. Comparison 1 Formoterol and ICS versus same dose ICS, Outcome 10 All-cause non-fatal
Serious Adverse Events (sensitivity analysis without unblinded study).
Review: Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events
Comparison: 1 Formoterol and ICS versus same dose ICS
Outcome: 10 All-cause non-fatal Serious Adverse Events (sensitivity analysis without unblinded study)
Study or subgroup Formoterol and ICS Same Dose ICS
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Adults and Adolescents
Buhl 2003 2/352 2/171 0.45 [ 0.06, 3.68 ]
Chuchalin 2002 0/111 2/114 0.14 [ 0.01, 2.22 ]
Corren 2007 2/123 0/121 7.33 [ 0.46, 117.87 ]
D5896C00001 3/312 0/153 4.47 [ 0.40, 49.92 ]
Jenkins 2006 7/341 3/115 0.77 [ 0.18, 3.26 ]
Kuna 2006 3/409 4/207 0.34 [ 0.07, 1.67 ]
Morice 2007 2/462 2/217 0.43 [ 0.05, 3.57 ]
Noonan 2006 7/239 0/109 4.40 [ 0.88, 22.04 ]
0.001 0.01 0.1 1 10 100 1000
Favours Formoterol % ICS Favours same dose ICS
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(. . . Continued)
Study or subgroup Formoterol and ICS Same Dose ICS
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
O’Byrne 2001 20/554 23/550 0.86 [ 0.47, 1.58 ]
O’Byrne 2001a 15/315 19/312 0.77 [ 0.39, 1.54 ]
Pauwels 1997 10/210 9/213 1.13 [ 0.45, 2.84 ]
Pauwels 1997a 15/215 12/214 1.26 [ 0.58, 2.75 ]
Peters 2008 21/443 5/133 1.26 [ 0.49, 3.19 ]
Price 2002 2/250 3/255 0.68 [ 0.12, 3.96 ]
SD-039-0726 4/301 1/145 1.78 [ 0.27, 11.65 ]
Zetterstrom 2001 3/238 1/124 1.51 [ 0.19, 12.04 ]
Subtotal (95% CI) 4875 3153 0.99 [ 0.74, 1.33 ]
Total events: 116 (Formoterol and ICS), 86 (Same Dose ICS)
Heterogeneity: Chi2 = 13.79, df = 15 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
2 Children and Adolescents
Morice 2008 2/415 3/207 0.30 [ 0.05, 1.93 ]
Pohunek 2006 8/417 3/213 1.35 [ 0.38, 4.74 ]
SD-039-0714 1/136 1/134 0.99 [ 0.06, 15.83 ]
SD-039-0718 0/128 0/145 0.0 [ 0.0, 0.0 ]
SD-039-0725 5/352 1/169 2.07 [ 0.37, 11.52 ]
Tal 2002 7/148 0/138 7.20 [ 1.61, 32.21 ]
Subtotal (95% CI) 1596 1006 1.69 [ 0.81, 3.54 ]
Total events: 23 (Formoterol and ICS), 8 (Same Dose ICS)
Heterogeneity: Chi2 = 7.24, df = 4 (P = 0.12); I2 =45%
Test for overall effect: Z = 1.39 (P = 0.16)
Total (95% CI) 6471 4159 1.06 [ 0.81, 1.40 ]
Total events: 139 (Formoterol and ICS), 94 (Same Dose ICS)
Heterogeneity: Chi2 = 22.78, df = 20 (P = 0.30); I2 =12%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 1.75, df = 1 (P = 0.19), I2 =43%
0.001 0.01 0.1 1 10 100 1000
Favours Formoterol % ICS Favours same dose ICS
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A D D I T I O N A L T A B L E S
Table 1. Dose and delivery of budesonide and formoterol
Study ID Daily Dose
of Budes-
onide (mcg
metered
dose)
Daily Dose
of
Formoterol
(mcg me-
tered dose)
Once Twice Combined Separate DPI PMDI
Buhl 2003 400 12 1 1 1 1
Chuchalin
2002
400 24 1 1 1
Corren
2007
400 24 1 1 1
D5896C00001
400 12/24 1 1 1 1
Jenkins
2006
1600 48 1 1 1 1
Kuna 2006 200 12 1 1 1 1
Morice
2007
800 24 1 1 1 1
Morice
2008
200
(children)
24 1 1 1 1
Noonan
2006
400 24 1 1 1 1 1
O’Byrne
2001
400 12 1 1 1
O’Byrne
2001a
800 12 1 1 1
Pauwels
1997
200 24 1 1 1
Pauwels
1997a
800 24 1 1 1
Peters 2008 1600 48 1 1 1
Pohunek
2006
400
(children)
24 1 1 1 1
Price 2002 800 24 1 1 1
80Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Dose and delivery of budesonide and formoterol (Continued)
SD-039-
0714
400 (adoles-
cents)
12 1 1 1
SD-039-
0718
200
(children)
24 1 1 1
SD-039-
0719
400
(children)
24 1 1 1
SD-039-
0725
200
(children)
12/24 1 1 1 1
SD-039-
0726
200 12/24 1 1 1 1
Tal 2002 400
(children)
24 1 1 1
Zetterstrom
2001
800 24 1 1 1 1
A P P E N D I C E S
Appendix 1. Pharmacology of beta2-agonists
ß-agonists are thought to cause bronchodilation primarily through binding beta2-adrenoceptors on airways smooth muscle (ASM),
with subsequent activation of both membrane-bound potassium channels and a signalling cascade involving enzyme activation and
changes in intracellular calcium levels following a rise in cyclic adenosine monophosphate (cAMP) (Barnes 1993). However, beta2-
adrenoceptors are also expressed on a wide range of cell types where beta2-agonists may have a clinically significant effect including
airway epithelium (Morrison 1993), mast cells, post capillary venules, sensory and cholinergic nerves and dendritic cells (Anderson
2006). Beta2-agonists will also cross-react to some extent with other beta-adrenoceptors including beta1-adrenoceptors on the heart.
The in vivo effect of any beta2-agonist will depend on a number of factors relating to both the drug and the patient. The degree to
which a drug binds to one receptor over another is known as selectivity, which can be defined as absolute binding ratios to different
receptors in vitro, whilst functional selectivity is measured from downstream effects of drugs in different tissue types in vitro or in vivo.
All of the beta2-agonists described thus far are more beta2 selective than their predecessor isoprenaline in vitro. However, because
attempts to differentiate selectivity between the newer agents are confounded by so many factors, it is difficult to draw conclusions
about in vitro selectivity studies and probably best to concentrate on specific adverse side-effects in human subjects at doses which
cause the same degree of bronchodilatation. The potency of a drug refers to the concentration that achieves half the maximal receptor
activation of which that drug is capable but it is not very important clinically as for each drug, manufacturers will alter the dose to try
to achieve a therapeutic ratio of desired to undesired effects. In contrast efficacy refers to the ability of a drug to activate its receptor
independent of drug concentration. Drugs that fully activate a receptor are known as full agonists and those that partially activate a
receptor are known as partial agonists. Efficacy also is very much dependent on the system in which it is being tested and is affected
by factors including the number of receptors available and the presence of other agonists and antagonists. Thus whilst salmeterol acts
as a partial agonist in vitro it causes a similar degree of bronchodilation to the strong agonist formoterol in stable asthmatic patients
(vanNoord 1996), presumably because there are an abundance of well-coupled beta2-adrenoceptors available with few downstream
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antagonising signals. In contrast, with repetitive dosing formoterol is significantly better than salmeterol at preventing methacholine-
induced bronchoconstriction (Palmqvist 1999). These differences have led to attempts to define the “intrinsic efficacy” of a drug
independent of tissue conditions (Hanania 2002), as shown in Table 1. The clinical significance of intrinsic efficacy remains unclear.
2 Po
Appendix 2. Possible mechanisms of increased asthma mortality with beta-agonists
Direct toxicity
This hypothesis states that direct adverse effects of beta2-agonists are responsible for an associated increase in mortality and most
research in the area has concentrated on effects detrimental to the heart. Whilst it is often assumed that cardiac side-effects of beta2-
agonists are due to cross-reactivity with beta1-adrenoceptors (i.e. poor selectivity), it is worth noting that human myocardium also
contains an abundance of beta2-adrenoceptors capable of triggering positive chronotropic and inotropic responses (Lipworth 1992).
Indeed, there is good evidence that cardiovascular side-effects of isoprenaline (Arnold 1985) and beta2-agonists including salbutamol
(Hall 1989) are mediated predominantly via cardiac beta2-adrenoceptors thus making the concept of in vitro selectivity less relevant.
Generalised beta2-adrenoceptor activation can also cause hypokalaemia (Brown 1983) and it has been proposed that, through these
and other actions, beta2-agonists may predispose to life-threatening dysrhythmias or cause other adverse cardiac effects.
During the 1960s epidemic most deaths occurred in patients with severe asthma and it was originally assumed that asthma and its
sequelae, including hypoxia, were the primary cause of death. However, mucus plugging and hypoxia does not preclude a cardiac event
as the final cause of death, and one might expect those with severe asthma to take more doses of a prescribed inhaler. As noted by Speizer
and Doll most deaths in the 1960s were in the 10-19 age group and “at these ages children have begun to act independently and may
be particularly prone to misuse a self-administered form of treatment” (Speizer 1968). If toxicity were related to increasing doses of
beta2-agonists one might expect most deaths to occur in hospital where high doses are typically used and this was not the case. One
possible explanation for this anomaly was provided by animal experiments in which large doses of isoprenaline caused little ill effect in
anaesthetised dogs with normal arterial oxygenation whereas much smaller doses caused fatal cardiac depression and asystole (although
no obvious dysrhythmia) when hypoxic (Collins 1969; McDevitt 1974). It has been hypothesised therefore that such events would be
less likely in hospital where supplemental oxygen is routinely given. The clinical relevance of these studies remains unclear although
there is some evidence of a synergistic effect between hypoxia and salbutamol use in asthmatic patients in reducing total peripheral
vascular resistance (Burggraaf 2001) - another beta2 mediated effect which could be detrimental to the heart during an acute asthma
attack through a reduction in diastolic blood pressure. Other potential mechanisms of isoprenaline toxicity include a potential increase
in mucous plugging and worsening of ventilation perfusion mismatch despite bronchodilation (Pearce 1990).
Further concerns about a possible toxic effect of beta2-agonists were raised during the New Zealand epidemic in the 1970s. In 1981
Wilson et al who first reported the epidemic reviewed 22 fatal cases of asthma and noted “In 16 patients death was seen to be sudden
and unexpected. Although all were experiencing respiratory distress, most were not cyanosed and the precipitate nature of their death
suggested a cardiac event, such as an arrest, inappropriate to the severity of their respiratory problem” (Wilson 1981). In humans,
fenoterol causes significantly greater chronotropic, inotropic and electrocardiographic side-effects than salbutamol in asthmatic patients
(Wong 1990). Interestingly, across the same parameters fenoterol also causes more side-effects than isoprenaline (Burgess 1991).
In patients with mild asthma and without a bronchoconstrictor challenge, salmeterol and salbutamol cause a similar degree of near
maximal bronchodilation at low doses (Bennett 1994). However, whilst as a one off dose salbutamol is typically used at 2-4 times the
concentration of salmeterol, the dose equivalences for salmeterol versus salbutamol in increasing heart rate and decreasing potassium
concentration and diastolic blood pressure were 17.7, 7.8 and 7.6 respectively (i.e. salmeterol had a greater effect across all parameters).
Given the lower intrinsic efficacy of salmeterol (Table 2), these results highlight the importance of in vivo factors; one possible explanation
for the difference is the increased lipophilicity of salmeterol compared to salbutamol contributing to higher systemic absorption (Bennett
1994).
When comparing increasing actuations of standard doses of formoterol and salmeterol inhalers in stable asthmatic patients, relatively
similar cardiovascular effects are seen at lower doses (Guhan 2000). However, at the highest doses (above those recommended by
the manufacturers) there were trends towards an increase in systolic blood pressure with formoterol; in comparison there was a trend
towards a decrease in diastolic blood pressure and an increase in QTc interval with salmeterol although no statistical analysis of the
difference was performed. In contrast in asthmatic patients with methacholine-induced bronchoconstriction there was no significant
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difference between salmeterol and formoterol in causing increased heart rate and QTc interval although formoterol caused significantly
greater bronchodilation and hypokalaemia (Palmqvist 1999). Whilst there is good evidence of cardiovascular and metabolic side-effects
with increasing doses of beta2-agonists, it is a little difficult to envisage serious adverse effects of this nature when using LABAs at
manufacturer-recommended preventative doses. However, it is possible that some patients choose to use repeated doses of LABAs
during exacerbations.
Tolerance
In this setting, the term tolerance refers to an impaired response to beta2-agonists in patients who have been using regular beta2-
agonist treatment previously (Haney 2006). Tolerance is likely to result from a combination of reduced receptor numbers secondary
to receptor internalisation and reduced production and also uncoupling of receptors to downstream signalling pathways following
repeated activation (Barnes 1995). This phenomenon is likely to explain the beneficial reduction in systemic side effects seen with
regular use of beta2-agonists including salbutamol after 1-2 weeks (Lipworth 1989). However, the same effect on beta2-adrenoceptors in
the lung might be expected to produce a diminished response to the bronchodilating activity of beta2-agonists following regular use. In
patients with stable asthma, whilst there is some evidence of tolerance to both salbutamol (Nelson 1977) and terbutaline (Weber 1982)
other studies have been less conclusive (Harvey 1982; Lipworth 1989). However, evidence of tolerance to short and long-acting beta2-
agonists in both protecting against and reducing bronchoconstriction is much stronger in the setting of an acute bronchoconstrictor
challenge with chemical, allergen and ’natural’ stimuli ( Haney 2006; Lipworth 1997).
Studies comparing salmeterol and formoterol have shown that both cause tolerance compared to placebo but there was no significant
difference between the drugs (van der Woude 2001). There also appears to be little difference in the tolerance induced by regular
formoterol and regular salbutamol treatment (Hancox 1999; Jones 2001). To the authors’ knowledge no studies have looked specifically
at the degree of tolerance caused by isoprenaline and fenoterol in the setting of acute bronchoconstriction. Tolerance to bronchodilation
has been shown to clearly occur with addition of inhaled corticosteroids to salmeterol and formoterol (Lee 2003) and terbutaline (Yates
1996). There is conflicting evidence as to whether high dose steroids can reverse tolerance in the acute setting (Lipworth 2000; Jones
2001).
At first glance the toxicity and tolerance hypotheses might appear incompatible as systemic and cardiovascular tolerance ought to
protect against toxicity in the acute setting and there is good evidence that such tolerance occurs in stable asthmatic patients (Lipworth
1989). However, whilst this study showed that changes in heart rate and potassium levels were blunted by previous beta2-agonist use,
they were not abolished; furthermore, at the doses studied these side-effects appear to follow an exponential pattern (Lipworth 1989).
In contrast, in the presence of bronchoconstrictor stimuli the bronchodilator response to beta2-agonists follows a flatter curve (Wong
1990; Hancox 1999) and as previously discussed this curve is shifted downwards by previous beta2-agonist exposure (Hancox 1999).
Thus, it is theoretically possible that in the setting of an acute asthmatic attack and strong bronchoconstricting stimuli, bronchodilator
tolerance could lead to repetitive beta2-agonist use and ultimately more systemic side-effects than would otherwise have occurred. Of
course, other sequelae of inadequate bronchodilation including airway obstruction will be detrimental in this setting.
Whilst the tolerance hypothesis is often cited as contributing towards the asthma mortality epidemics it is difficult to argue that
reduced efficacy of a drug can cause increased mortality relative to a time when that drug was not used at all. However, tolerance
to the bronchodilating effect of endogenous circulating adrenaline is theoretically possible and there is also evidence of rebound
bronchoconstriction when stopping fenoterol (Sears 1990), which may be detrimental. Furthermore, it appears that regular salbutamol
treatment can actually increase airway responsiveness to allergen (Cockcroft 1993) a potentially important effect that could form a
variant of the toxicity hypothesis. Differences between beta2-agonists in this regard are unclear, but the combination of rebound
hyperresponsiveness and tolerance of the bronchodilator effect with regular beta2-agonist exposure has been recently advocated as a
possible mechanism to explain the association between beta2-agonists and asthma mortality (Hancox 2006).
Other explanations
Confounding by severity
Historically, this hypothesis has been used extensively to try to explain the association between mortality and the use of fenoterol during
the 1970s New Zealand epidemic (see Pearce 2007) and is still quoted today. The hypothesis essentially relies on the supposition that
patients with more severe asthma are more likely to take either higher doses of beta2-agonists or a particular beta2-agonist (such as
fenoterol) thereby explaining the association. This hypothesis was carefully ruled out in the three case-control studies by comparing
the association between fenoterol and mortality in patients with varying severity of disease (Crane 1989; Pearce 1990; Grainger 1991).
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Furthermore, the hypothesis cannot explain the overall increase in mortality in the 1960s and 1970s nor can it explain any significant
increase in mortality (whether taking inhaled steroids or not) from randomised controlled trial data.
The delay hypothesis
This hypothesis accepts that beta2-agonists or a particular beta2-agonist cause an increased risk of mortality but indirectly by causing
patients to delay before getting medical help and further treatments including high dose steroids and oxygen. There is evidence that
both salmeterol and formoterol can reduce awareness of worsening underlying inflammation (Bijl-Hofland 2001; McIvor 1998). It
is difficult to rule out the delay hypothesis in either explaining or contributing towards both the asthma mortality epidemics and
an association with regular use of LABAs. There is evidence that beta2-agonists with higher intrinsic efficacy are more effective at
relieving bronchoconstriction in the acute setting (Hanania 2007) and could paradoxically cause patients to delay seeking medical help
for longer. For the delay hypothesis to explain the increase in mortality during the 1960s and 1970s one has to imply that hospital
treatment of asthma when mortality rates were low during the earlier years of the 20th century was effective. It is difficult to say exactly
how effective such treatment is likely to have been.
Reduced corticosteroid treatment
A slight but significant variation of the delay hypothesis suggests that patients who have separate beta2-agonists and corticosteroid
inhalers may choose to take less corticosteroid because of better symptom control from the inhaled beta2-agonists and it is reduced
corticosteroid treatment that contributes to a rise in mortality. It is rather difficult to see how this hypothesis explains the epidemics of
asthma deaths in the 1960s and 1970s relative to the 1920s and 30s (Figure 1), given that corticosteroids were not used for the treatment
of asthma in the earlier decades. If this hypothesis were to explain increased mortality from more recent randomised controlled trial
data one would not expect to see an increase in mortality in those taking LABAs alone.
Appendix 3. Definition of Serious Adverse Events
The Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH) define serious adverse events as follows (ICHE2a 1995):
“A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:
• Results in death,
• Is life-threatening,
• Requires inpatient hospitalization or prolongation of existing hospitalization,
• Results in persistent or significant disability/incapacity, or
• Is a congenital anomaly/birth defect.
NOTE: The term ”life-threatening“ in the definition of ”serious“ refers to an event in which the patient was at risk of death at the time
of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.”
H I S T O R Y
Protocol first published: Issue 1, 2008
Review first published: Issue 2, 2009
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